Revvity (RVTY) 10-Q 11 May 21 2021 Q1 Quarterly report Financial data

Cover Page

Cover Page - shares	3 Months Ended
	Apr. 04, 2021	May 06, 2021
Entity Listings [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Apr. 4, 2021
Document Transition Report	false
Entity File Number	001-5075
Entity Registrant Name	PERKINELMER INC
Entity Incorporation, State or Country Code	MA
Entity Tax Identification Number	04-2052042
Entity Address, Address Line One	940 Winter Street,
Entity Address, City or Town	Waltham,
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02451
City Area Code	781
Local Phone Number	663-6900
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		112,091,175
Entity Central Index Key	0000031791
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q1
Amendment Flag	false
Current Fiscal Year End Date	--01-02
PKI [Member]
Entity Listings [Line Items]
Trading Symbol	PKI
Trading Symbol	PKI
PKI 21A [Member]
Entity Listings [Line Items]
Trading Symbol	PKI 21A
Trading Symbol	PKI 21A
Common stock, $1 par value per share [Member]
Entity Listings [Line Items]
Title of 12(b) Security	Common stock, $1 par value per share
Title of 12(b) Security	Common stock, $1 par value per share
1.875% Notes due 2026 [Member]
Entity Listings [Line Items]
Title of 12(b) Security	1.875% Notes due 2026
Title of 12(b) Security	1.875% Notes due 2026
NEW YORK STOCK EXCHANGE, INC. [Member]
Entity Listings [Line Items]
Security Exchange Name	NYSE
Security Exchange Name	NYSE

Condensed Consolidated Income S

Condensed Consolidated Income Statements - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Apr. 04, 2021	Apr. 05, 2020
Revenue from Contract with Customer, Excluding Assessed Tax	$ 1,307,689	$ 652,396
Cost of Goods and Services Sold	522,543	344,373
Selling, general and administrative expenses	251,410	208,569
Research and development expenses	60,216	48,914
Restructuring and other costs, net	5,744	5,858
Operating income from continuing operations	467,776	44,682
Interest and other (income) expense, net	(12,706)	9,993
Interest And Other Expense Net	(12,706)	(9,993)
Income from continuing operations before income taxes	480,482	34,689
Provision for income taxes	101,139	974
Income from continuing operations	379,343	33,715
Loss on disposition of discontinued operations before income taxes	0	0
Provision for income taxes on discontinued operations and dispositions	38	50
Loss from discontinued operations and dispositions	(38)	(50)
Net income	$ 379,305	$ 33,665
Basic earnings (loss) per share:
Income (loss) from continuing operations (per share)	$ 3.39	$ 0.30
Gain (loss) on discontinued operations and dispositions (per share)	0	0
Net income (per share)	3.39	0.30
Diluted earnings (loss) per share:
Income (loss) from continuing operations (per share)	3.37	0.30
Gain (loss) on discontinued operations and dispositions (per share)	0	0
Net income (per share)	$ 3.37	$ 0.30
Weighted average shares of common stock outstanding:
Basic (in shares)	112,028	111,121
Diluted (in shares)	112,495	111,644
Cash dividends per common share	$ 0.07	$ 0.07
Product [Member]
Revenue from Contract with Customer, Excluding Assessed Tax	$ 811,552	$ 425,529
Cost of Goods and Services Sold	339,312	206,190
Service [Member]
Revenue from Contract with Customer, Excluding Assessed Tax	496,137	226,867
Cost of Goods and Services Sold	$ 183,231	$ 138,183

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Common Stock Amount [Member]	Capital In Excess of Par Value [Member]	Retained Earnings [Member]	Accumulated Other Comprehensive Income (Loss) [Member]
Beginning Balance at Dec. 29, 2019	$ 2,813,824	$ 111,140	$ 90,357	$ 2,811,973	$ (199,646)
Net income	33,665			33,665
Other comprehensive income (loss)	(78,681)
Dividends	(7,779)			(7,779)
Exercise of employee stock options and related income tax benefits	1,106	21	1,085
Issuance of common stock for employee benefit plans	(1,256)	(14)	(1,242)	0	0
Cost of Repurchased Common Shares, Repurchase Plan and Amount for Statutory Tax Withholding Obligations	(6,342)	(66)	(6,276)
Issuance of common stock for long-term incentive program	(3,028)	(197)	(2,831)
Stock compensation	997	0	997	0	0
Ending Balance at Apr. 05, 2020	2,759,746	111,306	90,236	2,836,531	(278,327)
Other Comprehensive Income (Loss), after Reclassifications, Net of Tax	(78,681)				(78,681)
Cumulative Effect of New Accounting Pronouncement in Period of Adoption | Accounting Standards Update 2016-02 [Member]	(1,328)	0	0	(1,328)	0
Beginning Balance at Jan. 03, 2021	3,735,492	112,090	148,101	3,507,262	(31,961)
Net income	379,305			379,305
Other comprehensive income (loss)	(72,211)
Dividends	(7,846)			(7,846)
Exercise of employee stock options and related income tax benefits	4,987	95	4,892
Issuance of common stock for employee benefit plans	(8)	0	(8)
Cost of Repurchased Common Shares, Repurchase Plan and Amount for Statutory Tax Withholding Obligations	(42,779)	(295)	(42,484)
Issuance of common stock for long-term incentive program	(4,450)	(176)	(4,274)
Stock compensation	899	0	899	0	0
Ending Balance at Apr. 04, 2021	4,002,305	$ 112,066	$ 115,690	$ 3,878,721	(104,172)
Other Comprehensive Income (Loss), after Reclassifications, Net of Tax	$ (72,211)				$ (72,211)

Condensed Consolidated Statemen

Condensed Consolidated Statements of Comprehensive Income - USD ($) $ in Thousands	3 Months Ended
	Apr. 04, 2021	Apr. 05, 2020
Net income	$ 379,305	$ 33,665
Other Comprehensive Income (Loss), Net of Tax [Abstract]
Foreign currency translation adjustments, net of income taxes	(72,305)	(78,593)
Unrealized gain (loss) on securities, net of income taxes	94	(88)
Other comprehensive loss	(72,211)	(78,681)
Comprehensive income (loss)	$ 307,094	$ (45,016)

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Apr. 04, 2021	Jan. 03, 2021
Current assets:
Cash and cash equivalents	$ 988,234	$ 402,036
Accounts receivable, net	978,598	1,155,109
Inventories	529,908	514,567
Other current assets	177,831	167,208
Total current assets	2,674,571	2,238,920
Property, plant and equipment, net:
Property, plant and equipment, net	371,102	368,304
Operating Lease, Right-of-Use Asset	213,306	207,236
Intangible assets, net	1,473,256	1,365,693
Goodwill	3,683,790	3,447,114
Other assets, net	346,700	333,048
Total assets	8,762,725	7,960,315
Current liabilities:
Current portion of long-term debt	358,435	380,948
Accounts payable	339,326	327,325
Accrued expenses and other current liabilities		4,700
Accrued expenses and other current liabilities	822,749	943,916
Total current liabilities	1,520,510	1,652,189
Long-term debt	2,219,670	1,609,701
Long-term liabilities	827,636	774,531
Operating Lease, Liability, Noncurrent	192,604	188,402
Total liabilities	4,760,420	4,224,823
Commitments and contingencies (see Note 18)
Stockholders' equity:
Preferred stock—$1 par value per share, authorized 1,000,000 shares; none issued or outstanding	0	0
Common stock—$1 par value per share, authorized 300,000,000 shares; issued and outstanding 112,066,000 shares and 112,090,000 shares at April 4, 2021 and January 3, 2021, respectively	112,066	112,090
Capital in excess of par value	115,690	148,101
Retained earnings	3,878,721	3,507,262
Accumulated other comprehensive loss	(104,172)	(31,961)
Total stockholders’ equity	4,002,305	3,735,492
Total liabilities and stockholders’ equity	$ 8,762,725	$ 7,960,315

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Apr. 04, 2021	Jan. 03, 2021
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 1	$ 1
Preferred stock, authorized	1,000,000	1,000,000
Preferred stock, issued	0	0
Preferred stock, outstanding	0	0
Common stock, par value	$ 1	$ 1
Common stock, authorized	300,000,000	300,000,000
Common stock, issued	112,066,000	112,090,000
Common stock, outstanding	112,066,000	112,090,000

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Apr. 04, 2021	Apr. 05, 2020
Operating activities:
Net income	$ 379,305	$ 33,665
Loss from discontinued operations and dispositions, net of income taxes	38	50
Income from continuing operations	379,343	33,715
Adjustments to reconcile net income from continuing operations to net cash provided by continuing operations:
Restructuring and other costs, net	5,744	5,858
Depreciation and amortization	70,186	60,758
Stock-based compensation	5,157	3,050
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability	240	(12,325)
Amortization of deferred debt financing costs and accretion of discounts	896	707
Change in fair value of financial securities	(19,298)	0
Amortization of acquired inventory revaluation	2,981	1,088
Changes in operating assets and liabilities which provided (used) cash, excluding effects from companies purchased and divested:
Accounts receivable, net	165,190	80,600
Inventories	(15,008)	(54,758)
Accounts payable	(5,048)	3,164
Accrued expenses and other	(116,883)	(61,807)
Net cash provided by operating activities	473,500	60,050
Investing activities:
Capital expenditures	(14,311)	(20,488)
Proceeds from surrender of life insurance policies	0	52
Payments to Acquire Investments	(4,000)	(1,638)
Proceeds from Divestiture of Businesses	0	60
Cash paid for acquisitions, net of cash, cash equivalents and restricted cash acquired	(443,543)	0
Net cash used in investing activities	(461,854)	(22,014)
Financing activities:
Payments of borrowings	743,545	141,000
Proceeds from borrowings	584,000	125,000
Proceeds from sale of senior debt	799,856	0
Payments of debt financing costs	(7,882)	0
Settlement of cash flow hedges	6,005	8,708
Net payments on other credit facilities	(9,799)	(4,283)
Proceeds from issuance of common stock under stock plans	4,987	1,106
Purchases of common stock	(42,779)	(6,342)
Dividends paid	(7,852)	(7,781)
Net cash provided by (used in) financing activities	582,991	(24,592)
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	(6,849)	(10,169)
Net increase (decrease) in cash, cash equivalents, restricted cash and restricted cash equivalent	587,788	3,275
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents at beginning of period	402,613	191,894
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents at end of period	990,401	195,169
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	$ 990,401	$ 195,169

Basis of Presentation

Basis of Presentation	3 Months Ended
	Apr. 04, 2021
Accounting Policies [Abstract]
Basis of Accounting [Text Block]	Basis of Presentation The condensed consolidated financial statements included herein have been prepared by PerkinElmer, Inc. (the “Company”), in accordance with accounting principles generally accepted in the United States of America (the “U.S.” or the "United States") and pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Certain information in the footnote disclosures of the financial statements has been condensed or omitted where it substantially duplicates information provided in the Company’s latest audited consolidated financial statements, in accordance with the rules and regulations of the SEC. These condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and notes included in its Annual Report on Form 10-K for the fiscal year ended January 3, 2021, filed with the SEC (the “2020 Form 10-K”). The balance sheet amounts at January 3, 2021 in this report were derived from the Company’s audited 2020 consolidated financial statements included in the 2020 Form 10-K. The condensed consolidated financial statements reflect all adjustments that, in the opinion of management, are necessary to present fairly the Company’s financial position, results of operations and cash flows for the periods indicated. The preparation of financial statements in conformity with U.S. Generally Accepted Accounting Principles (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts and classifications of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The results of operations for the three months ended April 4, 2021 and April 5, 2020, respectively, are not necessarily indicative of the results for the entire fiscal year or any future period. The Company’s fiscal year ends on the Sunday nearest December 31. The Company reports fiscal years under a 52/53 week format and as a result, certain fiscal years will contain 53 weeks. The fiscal year ending January 2, 2022 ("fiscal year 2021") will include 52 weeks, and the fiscal year ended January 3, 2021 ("fiscal year 2020") included 53 weeks. Recently Adopted and Issued Accounting Pronouncements: From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (the "FASB") and are adopted by the Company as of the specified effective dates. Unless otherwise discussed, such pronouncements did not have or will not have a significant impact on the Company’s consolidated financial position, results of operations and cash flows or do not apply to the Company’s operations. In December 2019, the FASB issued Accounting Standards Update No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes ("ASU 2019-12"). ASU 2019-12 eliminates certain exceptions and adds guidance to reduce complexity in accounting for income taxes. Specifically, this guidance: (1) removes the intraperiod tax allocation exception to the incremental approach; (2) removes the ownership changes in investments exception in determining when a deferred tax liability is recognized after an investor in a foreign entity transitions to or from the equity method of accounting and applies this provision on a modified retrospective basis through a cumulative-effect adjustment to retained earnings at the beginning of the period of adoption; and (3) removes the exception to using the general methodology for calculating income taxes in an interim period when a year-to-date loss exceeds the anticipated loss for the year. ASU 2019-12 also simplifies accounting principles by making other changes, including requiring an entity to: (1) evaluate whether a step-up in tax basis of goodwill relates to a business combination or a separate transaction; (2) make a policy election to not allocate consolidated income taxes when a member of a consolidated tax return is not subject to income tax and to apply this provision retrospectively to all periods presented; and (3) recognize a franchise tax (or similar tax) that is partially based on income as an income-based tax and apply this provision either retrospectively for all periods presented or on a modified retrospective basis through a cumulative-effect adjustment to retained earnings as of the beginning of the period of adoption. The provisions of this guidance (except as specifically mentioned above) are to be applied prospectively upon their effective date. ASU 2019-12 is effective for annual reporting periods beginning after December 15, 2020, and interim p eriods within those years. In accordance with ASU 2019-12, the Company adopted the guidance beginning on January 4, 2021. The adoption did not have a material impact on the Company's consolidated financial position, results of operations and cash flows.

Revenue (Notes)

Revenue (Notes) - USD ($) $ in Thousands	3 Months Ended
	Apr. 04, 2021	Apr. 05, 2020
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer [Text Block]	Revenue Disaggregation of revenue In the following tables, revenue is disaggregated by primary geographical markets, primary end-markets and timing of revenue recognition. The tables also include a reconciliation of the disaggregated revenue with the reportable segments' revenue. Reportable Segments Three Months Ended April 4, 2021 April 5, 2020 Discovery & Analytical Solutions Diagnostics Total Discovery & Analytical Solutions Diagnostics Total (In thousands) Primary geographical markets Americas $ 175,115 $ 400,927 $ 576,042 $ 169,116 $ 105,157 $ 274,273 Europe 135,458 311,743 447,201 118,657 81,599 200,256 Asia 144,036 140,410 284,446 110,622 67,245 177,867 $ 454,609 $ 853,080 $ 1,307,689 $ 398,395 $ 254,001 $ 652,396 Primary end-markets Diagnostics $ — $ 853,080 $ 853,080 $ — $ 254,001 $ 254,001 Life sciences 277,201 — 277,201 245,733 — 245,733 Applied markets 177,408 — 177,408 152,662 — 152,662 $ 454,609 $ 853,080 $ 1,307,689 $ 398,395 $ 254,001 $ 652,396 Timing of revenue recognition Products and services transferred at a point in time $ 326,662 $ 615,106 $ 941,768 $ 267,907 $ 231,653 $ 499,560 Services transferred over time 127,947 237,974 365,921 130,488 22,348 152,836 $ 454,609 $ 853,080 $ 1,307,689 $ 398,395 $ 254,001 $ 652,396 Major Customer Concentration Revenues from one customer in the Company's Diagnostics segment represent approximately $205.6 million of the Company's total revenue for the three months ended April 4, 2021. Contract Balances Contract assets: The unbilled receivables (contract assets) primarily relate to the Company's right to consideration for work completed but not billed at the reporting date. The unbilled receivables are transferred to trade receivables when billed to customers. Contract assets are generally classified as current assets and are included in "Accounts receivable, net" in the consolidated balance sheets. The balance of contract assets as of April 4, 2021 and January 3, 2021 were $50.2 million and $59.5 million, respectively. The amount of unbilled receivables recognized at the beginning of the period that were transferred to trade receivables during the three months ended April 4, 2021 was $37.8 million. The increase in unbilled receivables during the three months ended April 4, 2021 as a result of recognition of revenue before billing to customers, excluding amounts transferred to trade receivables during the period, amounted to $28.5 million. Contract liabilities: The contract liabilities primarily relate to the advance consideration received from customers for products and related installation for which transfer of control has not occurred at the balance sheet date. Contract liabilities are classified as either current in "Accounts payable" or "Accrued expenses and other current liabilities" or as long-term in "Long-term liabilities" in the consolidated balance sheets based on the timing of when the Company expects to recognize revenue. The balance of contract liabilities as of April 4, 2021 and January 3, 2021 were $221.0 million and $238.1 million, respectively. The increase in contract liabilities during the three months ended April 4, 2021 due to cash received, excluding amounts recognized as revenue during the period, was $20.9 million. The amount of revenue recognized during the three months ended April 4, 2021 that was included in the contract liability balance at the beginning of the period was $38.0 million. Contract costs: The Company recognizes the incremental costs of obtaining a contract with a customer as an asset if it expects the benefit of those costs to be longer than one year. The Company determined that certain sales incentive programs meet the requirements to be capitalized. Total capitalized costs to obtain a contract were immaterial during the period and are included in other current and long-term assets on the consolidated balance sheets. The Company applies a practical expedient to expense costs as incurred for costs to obtain a contract with a customer when the amortization period would have been one year or less. These costs include the Company's internal sales force compensation program, as the Company determined that annual compensation is commensurate with annual sales activities. Transaction price allocated to the remaining performance obligations
Revenue from Contract with Customer, Excluding Assessed Tax	$ 1,307,689	$ 652,396
Transferred at Point in Time [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	941,768	499,560
Transferred over Time [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	365,921	152,836
Americas [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	576,042	274,273
Europe [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	447,201	200,256
Asia [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	284,446	177,867
Diagnostics [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	853,080	254,001
Life Sciences [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	277,201	245,733
Applied Markets [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	177,408	152,662
Discovery & Analytical Solutions [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	454,609	398,395
Discovery & Analytical Solutions [Member] | Transferred at Point in Time [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	326,662	267,907
Discovery & Analytical Solutions [Member] | Transferred over Time [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	127,947	130,488
Discovery & Analytical Solutions [Member] | Americas [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	175,115	169,116
Discovery & Analytical Solutions [Member] | Europe [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	135,458	118,657
Discovery & Analytical Solutions [Member] | Asia [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	144,036	110,622
Discovery & Analytical Solutions [Member] | Diagnostics [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	0	0
Discovery & Analytical Solutions [Member] | Life Sciences [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	277,201	245,733
Discovery & Analytical Solutions [Member] | Applied Markets [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	177,408	152,662
Diagnostics [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	853,080	254,001
Diagnostics [Member] | Transferred at Point in Time [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	615,106	231,653
Diagnostics [Member] | Transferred over Time [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	237,974	22,348
Diagnostics [Member] | Americas [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	400,927	105,157
Diagnostics [Member] | Europe [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	311,743	81,599
Diagnostics [Member] | Asia [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	140,410	67,245
Diagnostics [Member] | Diagnostics [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	853,080	254,001
Diagnostics [Member] | Life Sciences [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	0	0
Diagnostics [Member] | Applied Markets [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	$ 0	$ 0

Business Combinations

Business Combinations	3 Months Ended
	Apr. 04, 2021
Business Combinations [Abstract]
Business Combinations	Business Combinations Acquisitions in fiscal year 2021 During the first quarter of fiscal year 2021, the Company completed the acquisition of two businesses for aggregate consideration of $593.4 million. The acquired businesses were Oxford Immunotec Global PLC ("Oxford"), a company based in Abingdon, UK with approximately 275 employees, which was acquired on March 8, 2021 for a total consideration of $590.9 million and one other business, which was acquired for a total consideration of $2.5 million. The excess of the purchase prices over the fair values of the acquired businesses' net assets represents cost and revenue synergies specific to the Company, as well as non-capitalizable intangible assets, such as employee workforces acquired, and has been allocated to goodwill, which is not tax deductible. The Company has reported the operations for these acquisitions within the results of the Company's Diagnostics and Discovery and Analytical Solutions segments, as applicable, from the acquisition dates. Identifiable definite-lived intangible assets, such as core technology, trade names, and customer relationships, acquired as part of these acquisitions had a weighted average amortization period of 11.1 years. The total purchase price for the acquisitions in fiscal year 2021 has been allocated to the estimated fair values of assets acquired and liabilities assumed as follows: Preliminary Oxford Other (In thousands) Fair value of business combination: Cash payments $ 590,865 $ 2,250 Other liability — 250 Less: cash acquired (149,586) — Total $ 441,279 $ 2,500 Identifiable assets acquired and liabilities assumed: Current assets $ 25,815 $ 25 Property, plant and equipment 12,404 65 Other assets 10,553 — Identifiable intangible assets: Core technology 150,000 2,410 Trade names 23,800 — Customer relationships 6,800 — Goodwill 280,944 — Deferred taxes (33,072) — Deferred revenue (102) — Debt assumed (331) — Liabilities assumed (35,532) — Total $ 441,279 $ 2,500 Acquisitions in fiscal year 2020 During the fiscal year 2020, the Company completed the acquisition of four businesses for aggregate consideration of $438.7 million. The acquired businesses were Horizon Discovery Group plc (“Horizon”), a company based in Cambridge, UK with approximately 400 employees, which was acquired on December 23, 2020 for a total consideration of $399.4 million (£296.0 million), and three other businesses, which were acquired for a total consideration of $39.3 million. The excess of the purchase prices over the fair values of the acquired businesses' net assets represents cost and revenue synergies specific to the Company, as well as non-capitalizable intangible assets, such as the employee workforces acquired, and has been allocated to goodwill, which is not tax deductible. The Company has reported the operations for these acquisitions within the results of the Company's Diagnostics and Discovery & Analytical Solutions segments, as applicable, from the acquisition dates. Identifiable definite-lived intangible assets, such as core technology, trade names, customer relationships and in-process research and development, acquired as part of these acquisitions had a weighted average amortization period of 11.0 years. The total purchase price for the acquisitions in fiscal year 2020 has been allocated to the estimated fair values of assets acquired and liabilities assumed as follows: Preliminary Horizon Other (In thousands) Fair value of business combination: Cash payments $ 399,005 $ 38,243 Other liability 396 1,263 Working capital and other adjustments — (384) Less: cash acquired (25,539) (1,300) Total $ 373,862 $ 37,822 Identifiable assets acquired and liabilities assumed: Current assets $ 29,762 $ 5,770 Property, plant and equipment 17,729 2,673 Other assets 17,743 371 Identifiable intangible assets: Core technology 60,000 5,730 Trade names 4,900 680 Customer relationships 97,600 10,923 Goodwill 202,071 16,016 Deferred taxes (22,651) (1,132) Deferred revenue (2,031) — Debt assumed — (29) Liabilities assumed (41,961) (3,180) Total $ 373,862 $ 37,822 The preliminary allocations of the purchase prices for acquisitions are based upon initial valuations. The Company's estimates and assumptions underlying the initial valuations are subject to the collection of information necessary to complete its valuations within the measurement periods, which are up to one year from the respective acquisition dates. The primary areas of the preliminary purchase price allocations that are not yet finalized relate to the fair value of certain tangible and intangible assets acquired and liabilities assumed, assets and liabilities related to income taxes and related valuation allowances, and residual goodwill. The Company expects to continue to obtain information to assist in determining the fair values of the net assets acquired at the acquisition dates during the measurement periods. During the measurement periods, the Company will adjust assets or liabilities if new information is obtained about facts and circumstances that existed as of the acquisition dates that, if known, would have resulted in the recognition of those assets and liabilities as of those dates. These adjustments will be made in the periods in which the amounts are determined and the cumulative effect of such adjustments will be calculated as if the adjustments had been completed as of the acquisition dates. All changes that do not qualify as adjustments made during the measurement periods are also included in current period earnings. Allocations of the purchase price for acquisitions are based on estimates of the fair value of the net assets acquired and are subject to adjustment upon finalization of the purchase price allocations. The accounting for business combinations requires estimates and judgments as to expectations for future cash flows of the acquired business, and the allocation of those cash flows to identifiable intangible assets, in determining the estimated fair values for assets acquired and liabilities assumed. As of April 4, 2021, the Company may have to pay contingent consideration related to acquisitions with open contingency periods of up to $7.3 million. As of April 4, 2021, the Company has recorded contingent consideration obligations of $3.1 million, of which $3.0 million was recorded in accrued expenses and other current liabilities, and $0.1 million was recorded in long-term liabilities. As of January 3, 2021, the Company had recorded contingent consideration obligations with an estimated fair value of $3.0 million, of which $2.9 million was recorded in accrued expenses and other current liabilities, and $0.1 million was recorded in long-term liabilities. The expected maximum earnout period for acquisitions with open contingency periods does not exceed 1.8 years from April 4, 2021, and the remaining weighted average expected earnout period at April 4, 2021 was 1.1 years. If the actual results differ from the estimates and judgments used in these fair values, the amounts recorded in the condensed consolidated financial statements could result in a possible impairment of the intangible assets and goodwill, require acceleration of the amortization expense of definite-lived intangible assets or the recognition of additional contingent consideration which would be recognized as a component of operating expenses from continuing operations. Total acquisition and divestiture-related costs for the three months ended April 4, 2021 and April 5, 2020 were $4.4 million and $12.4 million, respectively. These amounts included $5.4 million and $12.3 million of incentive award associated with the Company's acquisition of Meizheng Group for the three months ended April 4, 2021 and April 5, 2020, respectively. Net foreign exchange gain and interest expense related to the Company's acquisition of Oxford for the three months ended April 4, 2021 amounted to $5.4 million and $0.2 million, respectively. These acquisition and divestiture-related costs were expensed as incurred and recorded in selling, general and administrative expenses and interest and other expense, net in the Company's consolidated statements of operations.

Restructuring and Lease Charges

Restructuring and Lease Charges, Net	3 Months Ended
	Apr. 04, 2021
Restructuring and Related Activities [Abstract]
Restructuring and Lease Charges, Net	Restructuring and Other Costs, NetThe Company implemented a restructuring plan in the first quarter of fiscal year 2021 consisting of workforce reductions principally intended to realign resources to emphasize growth initiatives and integrate new acquisitions (the "Q1 2021 Plan"). The Company implemented a restructuring plan in the third quarter of fiscal year 2020 consisting of workforce reductions principally intended to realign resources to emphasize growth initiatives (the "Q3 2020 Plan"). The Company implemented a restructuring plan in the first quarter of fiscal year 2020 consisting of workforce reductions and closure of excess facilities principally intended to realign resources to emphasize growth initiatives (the "Q1 2020 Plan"). Details of the plans initiated in previous years (the “Previous Plans”) are discussed more fully in Note 5 to the audited consolidated financial statements in the 2020 Form 10-K. The following table summarizes the reductions in headcount, the initial restructuring or contract termination charges by reporting segment, and the dates by which payments were substantially completed, or the dates by which payments are expected to be substantially completed, for restructuring actions implemented during fiscal years 2021 and 2020 in continuing operations: Workforce Reductions Closure of Excess Facility Total (Expected) Date Payments Substantially Completed by Headcount Reduction Discovery & Analytical Solutions Diagnostics Discovery & Analytical Solutions Diagnostics Severance Excess Facility (In thousands, except headcount data) Q1 2021 Plan 77 $ 3,941 $ 1,615 $ — $ — $ 5,556 Q4 FY2021 — Q3 2020 Plan 23 2,080 901 — — 2,981 Q2 FY2021 — Q1 2020 Plan 32 2,312 1,134 92 682 4,220 Q4 FY2020 Q1 FY2022 The Company recorded pre-tax charges of $0.2 million and $1.4 million associated with relocating facilities during the three months ended April 4, 2021 and April 5, 2020, respectively, in the Discovery & Analytical Solutions segment. The Company expects to make payments on these relocation activities through end of fiscal year 2021. At April 4, 2021, the Company had $10.1 million recorded for accrued restructuring and other costs, of which $8.6 million was recorded in short-term accrued restructuring and other costs, $0.2 million was recorded in operating lease right-of-use assets, and $1.2 million was recorded in operating lease liabilities. At January 3, 2021, the Company had $8.3 million recorded for accrued restructuring and other costs, of which $4.7 million was recorded in short-term accrued restructuring and other costs, $0.3 million was recorded in operating lease right-of-use assets, $2.0 million was recorded in accrued expenses and other current liabilities, and $1.3 million was recorded in operating lease liabilities. The following table summarizes the Company's restructuring accrual balances and related activity by restructuring plan, as well as other accrual balances and related activity, during the three months ended April 4, 2021: Balance at January 3, 2021 2021 Charges 2021 Changes in Estimates, Net 2021 Amounts Paid Balance at April 4, 2021 (In thousands) Severance: Q1 2021 Plan $ — $ 5,556 $ — $ (917) $ 4,639 Q3 2020 Plan 1,167 — — (443) 724 Q1 2020 Plan 872 — — (268) 604 Facility: Q1 2020 Plan 394 — — (85) 309 Previous Plans 3,550 — — (106) 3,444 Restructuring 5,983 5,556 — (1,819) 9,720 Contract Termination 318 — 35 (15) 338 Other Costs 1,998 188 — (2,186) — Total Restructuring and Other Liabilities $ 8,299 $ 5,744 $ 35 $ (4,020) $ 10,058

Interest and Other Expense (Inc

Interest and Other Expense (Income), Net	3 Months Ended
	Apr. 04, 2021
Other Income and Expenses [Abstract]
Interest and Other Expense (Income), Net	Interest and Other Expense, Net Interest and other expense, net, consisted of the following: Three Months Ended April 4, April 5, (In thousands) Interest income $ (411) $ (265) Interest expense 14,126 13,665 Change in fair value of financial securities (19,298) — Other income, net (7,123) (3,407) Total interest and other (income) expense, net $ (12,706) $ 9,993

Inventories, Net

Inventories, Net	3 Months Ended
	Apr. 04, 2021
Inventory Disclosure [Abstract]
Inventories, Net	Inventories Inventories as of April 4, 2021 and January 3, 2021 consisted of the following: April 4, January 3, (In thousands) Raw materials $ 196,712 $ 205,022 Work in progress 44,676 35,160 Finished goods 288,520 274,385 Total inventories $ 529,908 $ 514,567

Income Taxes

Income Taxes	3 Months Ended
	Apr. 04, 2021
Income Tax Disclosure [Abstract]
Income Taxes	Income TaxesDuring the first three months of fiscal years 2021 and 2020, the Company recorded a net discrete income tax expense of $2.0 million and a net discrete income tax benefit of $4.9 million, respectively. The primary components of the discrete tax expense in the first three months of fiscal year 2021 included various tax return to provision adjustments totaling $1.8 million and a $1.5 million accrual for foreign earnings, which were partially offset by excess tax benefits on stock compensation of $3.1 million. The most significant discrete tax benefits in the first three months of fiscal year 2020 included excess tax benefits on stock compensation of $1.6 million and $3.8 million associated with a valuation allowance reversal.

Debt

Debt	3 Months Ended
	Apr. 04, 2021
Debt Disclosure [Abstract]
Debt	Debt Senior Unsecured Revolving Credit Facility. The Company's senior unsecured revolving credit facility provides for $1.0 billion of revolving loans that may be either US Dollar Base Rate loans or Eurocurrency Rate loans, as those terms are defined in the credit agreement, and has an initial maturity of September 17, 2024. As of April 4, 2021, the senior unsecured revolving credit facility had no outstanding borrowings, and $2.4 million of unamortized debt issuance costs. As of January 3, 2021, the senior unsecured revolving credit facility had outstanding borrowings of $158.6 million, and $2.6 million of unamortized debt issuance costs. 1.875% Senior Unsecured Notes due 2026. On July 19, 2016, the Company issued €500.0 million aggregate principal amount of senior unsecured notes due in 2026 (the “2026 Notes”) in a registered public offering and received approximately €492.3 million of net proceeds from the issuance. The 2026 Notes were issued at 99.118% of the principal amount, which resulted in a discount of €4.4 million. The 2026 Notes mature in July 2026 and bear interest at an annual rate of 1.875%. Interest on the 2026 Notes is payable annually on July 19th each year. The proceeds from the 2026 Notes were used to pay in full the outstanding balance of the Company's previous senior unsecured revolving credit facility. As of April 4, 2021, the 2026 Notes had an aggregate carrying value of $582.4 million, net of $3.0 million of unamortized original issue discount and $2.7 million of unamortized debt issuance costs. As of January 3, 2021, the 2026 Notes had an aggregate carrying value of $604.7 million, net of $3.3 million of unamortized original issue discount and $2.8 million of unamortized debt issuance costs. 0.6% Senior Unsecured Notes due in 2021. On April 11, 2018, the Company issued €300.0 million aggregate principal amount of senior unsecured notes due in 2021 (the “2021 Notes”) in a registered public offering and received approximately €298.7 million of net proceeds from the issuance. The 2021 Notes were issued at 99.95% of the principal amount, which resulted in a discount of €0.2 million. As of April 4, 2021, the 2021 Notes had an aggregate carrying value of $352.8 million, net of $656 of unamortized original issue discount and $9,631 of unamortized debt issuance costs. As of January 3, 2021, the 2021 Notes had an aggregate carrying value of $366.2 million, net of $16,200 of unamortized original issue discount and $0.2 million of unamortized debt issuance costs. The 2021 Notes matured in April 2021 and bore interest at an annual rate of 0.6%. Interest on the 2021 Notes was payable annually on April 9th each year. On April 9, 2021, the Company redeemed all of its outstanding 2021 Notes and paid an aggregate principal amount of $337.1 million. 3.3% Senior Unsecured Notes due in 2029. On September 12, 2019, the Company issued $850.0 million aggregate principal amount of senior unsecured notes due in 2029 (the "2029 Notes”) in a registered public offering and received $847.2 million of net proceeds from the issuance. The 2029 Notes were issued at 99.67% of the principal amount, which resulted in a discount of $2.8 million. As of April 4, 2021, the 2029 Notes had an aggregate carrying value of $840.8 million, net of $2.4 million of unamortized original issue discount and $6.8 million of unamortized debt issuance costs. As of January 3, 2021, the 2029 Notes had an aggregate carrying value of $840.6 million, net of $2.5 million of unamortized original issue discount and $6.9 million of unamortized debt issuance costs. The 2029 Notes mature in September 2029 and bear interest at an annual rate of 3.3%. Interest on the 2029 Notes is payable semi-annually on March 15th and September 15th each year. 2.55% Senior Unsecured Notes due in 2031. On March 8, 2021, the Company issued $400.0 million aggregate principal amount of senior unsecured notes due in 2031 (the "2031 Notes”) in a registered public offering and received $399.9 million of net proceeds from the issuance. The 2031 Notes were issued at 99.965% of the principal amount, which resulted in a discount of $0.1 million. As of April 4, 2021, the 2031 Notes had an aggregate carrying value of $396.1 million, net of $0.1 million of unamortized original issue discount and $3.8 million of unamortized debt issuance costs. The 2031 Notes mature in March 2031 and bear interest at an annual rate of 2.55%. Interest on the 2031 Notes is payable semi-annually on March 15th and September 15th each year. Prior to December 15, 2030 (three months prior to their maturity date), the Company may redeem the 2031 Notes in whole at any time or in part from time to time, at its option, at a redemption price equal to the greater of (1) 100% of the principal amount of the 2031 Notes to be redeemed and (2) the sum of the present values of the remaining scheduled payments of principal and interest thereon (not including any portion of such payments of interest accrued but unpaid as of the date of redemption) assuming that the 2031 Notes matured on December 15, 2030, discounted to the date of redemption on a semi-annual basis (assuming a 360-day year of twelve 30-day months), at the Treasury Rate (as defined in the indenture governing the 2031 Notes) plus 15 basis points, plus accrued and unpaid interest thereon to, but excluding, the date of redemption. At any time on or after December 15, 2030, the Company may redeem the 2031 Notes, in whole or in part, at the Company’s option, at a redemption price equal to 100% of the principal amount of the 2031 Notes due to be redeemed plus accrued and unpaid interest, if any, to, but excluding, the date of redemption. Upon a change of control repurchase event (as defined in the indenture governing the 2031 Notes) of the Company, the Company will, in certain circumstances, make an offer to repurchase the 2031 Notes at a price equal to 101% of their principal amount plus any accrued and unpaid interest, if any, to, but excluding, the date of repurchase. 3.625% Senior Unsecured Notes due in 2051. On March 8, 2021, the Company issued $400.0 million aggregate principal amount of senior unsecured notes due in 2051 (the "2051 Notes”) in a registered public offering and received $400.00 million of net proceeds from the issuance. The 2051 Notes were issued at 99.999% of the principal amount, which resulted in a discount of $4,000. As of April 4, 2021, the 2051 Notes had an aggregate carrying value of $395.3 million, net of $4,000 of unamortized original issue discount and $4.7 million of unamortized debt issuance costs. The 2051 Notes mature in March 2051 and bear interest at an annual rate of 3.625%. Interest on the 2051 Notes is payable semi-annually on March 15th and September 15th each year. Prior to September 15, 2050 (six months prior to their maturity date), the Company may redeem the 2051 Notes in whole at any time or in part from time to time, at its option, at a redemption price equal to the greater of (1) 100% of the principal amount of the 2051 Notes to be redeemed and (2) the sum of the present values of the remaining scheduled payments of principal and interest thereon (not including any portion of such payments of interest accrued but unpaid as of the date of redemption) assuming that the 2051 Notes matured on September 15, 2050, discounted to the date of redemption on a semi-annual basis (assuming a 360-day year of twelve 30-day months), at the Treasury Rate (as defined in the indenture governing the 2051 Notes) plus 20 basis points, plus accrued and unpaid interest thereon to, but excluding, the date of redemption. At any time on or after September 15, 2050, the Company may redeem the 2051 Notes, in whole or in part, at the Company’s option, at a redemption price equal to 100% of the principal amount of the 2051 Notes due to be redeemed plus accrued and unpaid interest, if any, to, but excluding, the date of redemption. Upon a change of control repurchase event (as defined in the indenture governing the 2051 Notes) of the Company, the Company will, in certain circumstances, make an offer to repurchase the 2051 Notes at a price equal to 101% of their principal amount plus any accrued and unpaid interest, if any, to, but excluding, the date of repurchase. Other Debt Facilities. The Company's other debt facilities include Euro-denominated bank loans with an aggregate carrying value of $11.9 million (or €10.1 million) and $17.0 million (or €13.9 million) as of April 4, 2021 and January 3, 2021, respectively. These bank loans are primarily utilized for financing fixed assets and are required to be repaid in monthly or quarterly installments with maturity dates extending to 2028. In addition, the Company had secured bank loans in the aggregate amount of $0.8 million and $6.1 million as of April 4, 2021 and January 3, 2021, respectively. The secured bank loans are required to be repaid in monthly installments until 2022.

Earnings Per Share

Earnings Per Share	3 Months Ended
	Apr. 04, 2021
Earnings Per Share [Abstract]
Earnings Per Share	Earnings Per Share Basic earnings per share was computed by dividing net income by the weighted-average number of common shares outstanding during the period less restricted unvested shares. Diluted earnings per share was computed by dividing net income by the weighted-average number of common shares outstanding plus all potentially dilutive common stock equivalents, primarily shares issuable upon the exercise of stock options using the treasury stock method. The following table reconciles the number of shares utilized in the earnings per share calculations: Three Months Ended April 4, April 5, (In thousands) Number of common shares—basic 112,028 111,121 Effect of dilutive securities: Stock options 359 480 Restricted stock awards 108 43 Number of common shares—diluted 112,495 111,644 Number of potentially dilutive securities excluded from calculation due to antidilutive impact 162 491 Antidilutive securities include outstanding stock options with exercise prices and average unrecognized compensation cost in excess of the average fair market value of common stock for the related period. Antidilutive options were excluded from the calculation of diluted net income per share and could become dilutive in the future.

Industry Segment Information

Industry Segment Information	3 Months Ended
	Apr. 04, 2021
Segment Reporting [Abstract]
Industry Segment Information	Industry Segment Information The Company discloses information about its operating segments based on the way that management organizes the segments within the Company for making operating decisions and assessing financial performance. The Company evaluates the performance of its operating segments based on revenue and operating income. Intersegment revenue and transfers are not significant. The accounting policies of the operating segments are the same as those described in Note 1 to the audited consolidated financial statements in the 2020 Form 10-K. The principal products and services of the Company's two operating segments are: • Discovery & Analytical Solutions . Provides products and services targeted towards the life sciences and applied markets. • Diagnostics . Develops diagnostics, tools and applications focused on clinically-oriented customers, especially within the reproductive health, immunodiagnostics and applied genomics markets. The Diagnostics segment serves the diagnostics market. The Company has included the expenses for its corporate headquarters, such as legal, tax, audit, human resources, information technology, and other management and compliance costs, as well as the activity related to the mark-to-market adjustment on postretirement benefit plans, as “Corporate” below. The Company has a process to allocate and recharge expenses to the reportable segments when these costs are administered or paid by the corporate headquarters based on the extent to which the segment benefited from the expenses. These amounts have been calculated in a consistent manner and are included in the Company’s calculations of segment results to internally plan and assess the performance of each segment for all purposes, including determining the compensation of the business leaders for each of the Company’s operating segments. Revenue and operating income (loss) from continuing operations by operating segment are shown in the table below: Three Months Ended April 4, April 5, (In thousands) Discovery & Analytical Solutions Product revenue $ 267,255 $ 215,356 Service revenue 187,354 183,039 Total revenue 454,609 398,395 Operating income from continuing operations 42,947 28,513 Diagnostics Product revenue 544,297 210,173 Service revenue 308,783 43,828 Total revenue 853,080 254,001 Operating income from continuing operations 441,467 29,591 Corporate Operating loss from continuing operations (16,638) (13,422) Continuing Operations Product revenue 811,552 425,529 Service revenue 496,137 226,867 Total revenue 1,307,689 652,396 Operating income from continuing operations 467,776 44,682 Interest and other (income) expense, net (see Note 5) (12,706) 9,993 Income from continuing operations before income taxes $ 480,482 $ 34,689

Stockholders' Equity

Stockholders' Equity	3 Months Ended
	Apr. 04, 2021
Stockholders' Equity Note [Abstract]
Stockholders' Equity	Stockholders’ Equity Comprehensive Income: The components of accumulated other comprehensive loss consisted of the following: April 4, January 3, (In thousands) Foreign currency translation adjustments, net of income taxes $ (103,242) $ (30,937) Unrecognized prior service costs, net of income taxes (747) (747) Unrealized net losses on securities, net of income taxes (183) (277) Accumulated other comprehensive loss $ (104,172) $ (31,961) Stock Repurchases: On July 31, 2020, the Company's Board of Directors (the "Board") authorized the Company to repurchase shares of common stock for an aggregate amount up to $250.0 million under a stock repurchase program (the "Repurchase Program"). The Repurchase Program will expire on July 27, 2022 unless terminated earlier by the Board and may be suspended or discontinued at any time. During the three months ended April 4, 2021, the Company repurchased 233,000 shares of common stock under the Repurchase Program for an aggregate cost of $33.6 million. As of April 4, 2021, $216.4 million remained available for aggregate repurchases of shares under the Repurchase Program. In addition, the Board has authorized the Company to repurchase shares of common stock to satisfy minimum statutory tax withholding obligations in connection with the vesting of restricted stock awards and restricted stock unit awards granted pursuant to the Company’s equity incentive plans and to satisfy obligations related to the exercise of stock options made pursuant to the Company's equity incentive plans. During the three months ended April 4, 2021, the Company repurchased 61,791 shares of common stock for this purpose at an aggregate cost of $9.2 million. The repurchased shares have been reflected as additional authorized but unissued shares, with the payments reflected in common stock and capital in excess of par value. Dividends: The Board declared a regular quarterly cash dividend of $0.07 per share for the first quarter of fiscal year 2021 and in each quarter of fiscal year 2020. At April 4, 2021, the Company had accrued $7.9 million for dividends declared on January 28, 2021 for the first quarter of fiscal year 2021 that were paid on May 7, 2021. On April 29, 2021, the Company announced that the Board had declared a quarterly dividend of $0.07 per share for the second quarter of fiscal year 2021 that will be payable in August 2021. In the future, the Board may determine to reduce or eliminate the Company’s common stock dividend in order to fund investments for growth, repurchase shares or conserve capital resources.

Stock Plans

Stock Plans	3 Months Ended
	Apr. 04, 2021
Share-based Payment Arrangement [Abstract]
Stock Plans	Stock Plans The following table summarizes total pre-tax compensation expense recognized related to the Company’s stock option grants, restricted stock awards, performance restricted stock units, performance units and stock awards, included in the Company’s condensed consolidated statements of operations for the three months ended April 4, 2021 and April 5, 2020: Three Months Ended April 4, April 5, (In thousands) Cost of revenue $ 396 $ 254 Research and development expenses 197 272 Selling, general and administrative expenses 4,564 2,524 Total stock-based compensation expense $ 5,157 $ 3,050 The total income tax benefit recognized in the condensed consolidated statements of operations for stock-based compensation was $4.1 million and $2.2 million for the three months ended April 4, 2021 and April 5, 2020, respectively. Stock-based compensation costs capitalized as part of inventory were $0.5 million and $0.3 million as of April 4, 2021 and April 5, 2020, respectively. Stock Options : The fair value of each option grant is estimated using the Black-Scholes option pricing model. The Company’s weighted-average assumptions used in the Black-Scholes option pricing model were as follows: Three Months Ended April 4, April 5, Risk-free interest rate 0.6 % 0.9 % Expected dividend yield 0.2 % 0.3 % Expected term 5 years 5 years Expected stock volatility 27.3 % 23.8 % The following table summarizes stock option activity for the three months ended April 4, 2021: Number Weighted- Weighted-Average Total (In thousands) (In years) (In millions) Outstanding at January 3, 2021 961 $ 74.40 Granted 162 134.53 Exercised (96) 53.98 Forfeited (7) 88.54 Outstanding at April 4, 2021 1,020 $ 85.78 4.3 $ 46.2 Exercisable at April 4, 2021 640 $ 72.63 3.2 $ 36.7 The weighted-average per-share grant-date fair value of options granted during the three months ended April 4, 2021 and April 5, 2020 was $32.90 and $18.98. The total intrinsic value of options exercised during the three months ended April 4, 2021 and April 5, 2020 was $9.5 million and $0.9 million, respectively. Cash received from option exercises for the three months ended April 4, 2021 and April 5, 2020 was $5.0 million and $1.1 million, respectively. The total compensation expense recognized related to the Company’s outstanding options was $0.9 million and $1.0 million for the three months ended April 4, 2021 and April 5, 2020, respectively. There was $8.9 million of total unrecognized compensation cost related to nonvested stock options granted as of April 4, 2021. This cost is expected to be recognized over a weighted-average period of 2.3 years. Restricted Stock Awards : The following table summarizes restricted stock award activity for the three months ended April 4, 2021: Number of Weighted- (In thousands) Nonvested at January 3, 2021 296 $ 85.67 Granted 102 129.27 Vested (102) 83.16 Forfeited (5) 86.90 Nonvested at April 4, 2021 291 $ 101.83 The fair value of restricted stock awards vested during the three months ended April 4, 2021 and April 5, 2020 was $8.5 million and $11.6 million, respectively. The total compensation expense recognized related to the Company’s outstanding restricted stock awards was $2.8 million and $2.4 million for the three months ended April 4, 2021 and April 5, 2020, respectively. As of April 4, 2021, there was $23.4 million of total unrecognized compensation cost related to nonvested restricted stock awards. This cost is expected to be recognized over a weighted-average period of 1.8 years. Performance Restricted Stock Units: As part of the Company's executive compensation program, the Company granted 77,373 performance restricted stock units during the three months ended April 4, 2021 that will vest based on performance of the Company. The weighted-average per-share grant date fair value of performance restricted stock units granted during the three months ended April 4, 2021 was $113.44. During the three months ended April 4, 2021, no performance restricted stock units were forfeited. The total compensation expense recognized related to performance restricted stock units was $1.4 million and $0.6 million for the three months ended April 4, 2021 and April 5, 2020, respectively. As of April 4, 2021, there were 128,386 performance restricted stock units outstanding. Performance Units : No performance units were granted during the three months ended April 4, 2021. During the three months ended April 4, 2021, no performance units were forfeited. The total compensation expense (income) recognized related to performance units was $0.1 million and $(1.0) million for the three months ended April 4, 2021 and April 5, 2020, respectively. As of April 4, 2021, there were no performance units outstanding. Stock Awards : The Company’s stock award program provides an annual equity award to non-employee directors. During the three months ended April 4, 2021, the Company awarded no shares to non-employee directors. The total compensation expense recognized related to the stock awards were minimal for the three months ended April 5, 2020. Employee Stock Purchase Plan : During the three months ended April 4, 2021, the Company issued 58 shares of common stock under the Company's Employee Stock Purchase Plan at a weighted-average price of $136.33 per share. During the three months ended April 5, 2020, the Company issued 13,612 shares of common stock under the Company's Employee Stock Purchase Plan at a weighted-average price of $92.25 per share. At April 4, 2021, an aggregate of 0.8 million shares of the Company’s common stock remained available for sale to employees out of the 5.0 million shares authorized by shareholders for issuance under this plan.

Goodwill and Intangible Assets,

Goodwill and Intangible Assets, Net	3 Months Ended
	Apr. 04, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets, Net	Goodwill and Intangible Assets, Net The Company tests goodwill and non-amortizing intangible assets at least annually for possible impairment. Accordingly, the Company completes the annual testing of impairment for goodwill and non-amortizing intangible assets on the later of January 1 or the first day of each fiscal year. In addition to its annual test, the Company regularly evaluates whether events or circumstances have occurred that may indicate a potential impairment of goodwill or non-amortizing intangible assets. The process of testing goodwill for impairment involves the determination of the fair value of the applicable reporting units. The test consists of the comparison of the fair value to the carrying value of the reporting unit to determine if the carrying value exceeds the fair value. If the carrying value of the reporting unit exceeds its fair value, an impairment loss in an amount equal to that excess is recognized up to the amount of goodwill . The Company performed its annual impairment testing for its reporting units as of January 4, 2021, its annual impairment testing date for fiscal year 2021. The Company concluded that there was no goodwill impairment, and the fair value exceeded the carrying value by more than 20% for each reporting unit, except for the Company's Tulip reporting unit which had a fair value that was between 10% and 20% more than its carrying value. The range of the long-term terminal growth rates for the Compa ny’s reporting units was 3% to 5% for the fiscal year 2021 impairment analysis. The range for the discount rates for the reporting units was 8.0% to 12.5%. Keeping all other variables constant, a 10% change in any one of these input assumptions for the various reporting units, except for the Tulip reporting unit, would still allow the Company to conclude that there was no impairment of goodwill. As of January 4, 2021, the Company's Tulip reporting unit, which had a goodwill balance of $77.8 million, was at increased risk of an impairment charge given its ongoing weakness due to the impact of COVID-19. Despite the increased risk associated with this reporting unit, the Company does not currently expect a significant change in the key estimates or assumptions driving the fair value of this reporting unit that would lead to a material impairment charge. The Company has consistently employed the income approach to estimate the current fair value when testing for impairment of goodwill. A number of significant assumptions and estimates are involved in the application of the income approach to forecast operating cash flows, including markets and market share, sales volumes and prices, costs to produce, tax rates, capital spending, discount rates and working capital changes. Cash flow forecasts are based on approved business unit operating plans for the early years’ cash flows and historical relationships in later years. The income approach is sensitive to changes in long-term terminal growth rates and the discount rates. The long-term terminal growth rates are consistent with the Company’s historical long-term terminal growth rates, as the current economic trends are not expected to affect the long-term terminal growth rates of the Company. The Company corroborates the income approach with a market approach. Non-amortizing intangibles are also subject to an annual impairment test. The Company has consistently employed the relief from royalty model to estimate the current fair value when testing for impairment of non-amortizing intangible assets. The impairment test consists of a comparison of the fair value of the non-amortizing intangible asset with its carrying amount. If the carrying amount of a non-amortizing intangible asset exceeds its fair value, an impairment loss in an amount equal to that excess is recognized up to the amount of the amortizing intangible asset. In addition, the Company evaluates the remaining useful life of its non-amortizing intangible asset at least annually to determine whether events or circumstances continue to support an indefinite useful life. If events or circumstances indicate that the useful life of the Company's non-amortizing intangible asset is no longer indefinite, the asset will be tested for impairment. This intangible asset will then be amortized prospectively over its estimated remaining useful life and accounted for in the same manner as other intangible assets that are subject to amortization. The Company performed its annual impairment testing as of January 4, 2021 and concluded that there was no impairment of its non-amortizing intangible asset. An assessment of the recoverability of amortizing intangible assets takes place when events have occurred that may give rise to an impairment. No such events occurred during the first three months of fiscal year 2021. The changes in the carrying amount of goodwill for the three months ended April 4, 2021 were as follows: Discovery & Analytical Solutions Diagnostics Consolidated (In thousands) Balance at January 3, 2021 $ 1,755,887 $ 1,691,227 $ 3,447,114 Foreign currency translation (23,119) (22,268) (45,387) Acquisitions, earn-outs and other 1,326 280,737 282,063 Balance at April 4, 2021 $ 1,734,094 $ 1,949,696 $ 3,683,790 Identifiable intangible asset balances by category were as follows: April 4, January 3, (In thousands) Patents $ 30,843 $ 30,855 Less: Accumulated amortization (28,484) (28,440) Net patents 2,359 2,415 Trade names and trademarks 120,444 98,661 Less: Accumulated amortization (49,853) (48,806) Net trade names and trademarks 70,591 49,855 Licenses 58,705 58,700 Less: Accumulated amortization (53,005) (52,452) Net licenses 5,700 6,248 Core technology 936,682 789,799 Less: Accumulated amortization (411,558) (398,992) Net core technology 525,124 390,807 Customer relationships 1,334,715 1,357,660 Less: Accumulated amortization (546,783) (522,820) Net customer relationships 787,932 834,840 In-process research and development 10,966 10,944 Net amortizable intangible assets 1,402,672 1,295,109 Non-amortizing intangible asset: Trade name 70,584 70,584 Total $ 1,473,256 $ 1,365,693

Warranty Reserves

Warranty Reserves	3 Months Ended
	Apr. 04, 2021
Product Warranties Disclosures [Abstract]
Warranty Reserves	Warranty Reserves The Company provides warranty protection for certain products usually for a period of one year beyond the date of sale. The majority of costs associated with warranty obligations include the replacement of parts and the time for service personnel to respond to repair and replacement requests. A warranty reserve is recorded based upon historical results, supplemented by management’s expectations of future costs. Warranty reserves are included in “Accrued expenses and other current liabilities” on the condensed consolidated balance sheets. A summary of warranty reserve activity is as follows: Three Months Ended April 4, April 5, (In thousands) Balance at beginning of period $ 12,073 $ 8,812 Provision charged to income 3,691 2,712 Payments (6,182) (3,266) Adjustments to previously provided warranties, net 2,455 1,052 Foreign currency translation and acquisitions (190) (269) Balance at end of period $ 11,847 $ 9,041

Employee Benefit Plans

Employee Benefit Plans	3 Months Ended
	Apr. 04, 2021
Retirement Benefits [Abstract]
Employee Benefit Plans	Employee Postretirement Benefit Plans The following table summarizes the components of net periodic pension credit for the Company’s various defined benefit employee pension and postretirement plans: Defined Benefit Postretirement Three Months Ended April 4, April 5, April 4, April 5, (In thousands) Service and administrative costs $ 1,334 $ 1,907 $ 14 $ 18 Interest cost 2,377 3,144 17 24 Expected return on plan assets (6,127) (5,384) (397) (347) Net periodic pension credit $ (2,416) $ (333) $ (366) $ (305) During the three months ended April 4, 2021 and April 5, 2020, the Company contributed $1.8 million and $2.1 million, respectively, in the aggregate, to pension plans outside of the United States. During the three months ended April 4, 2021, the Company contributed $20.0 million to its defined benefit pension plan in the United States for the plan year 2019. The Company recognizes actuarial gains and losses, unless an interim remeasurement is required, in the fourth quarter of the year in which the gains and losses occur, in accordance with the Company's accounting method for defined benefit pension plans and other postretirement benefits as described in Note 1 of the Company's audited consolidated financial statements and notes included in its 2020 Form 10-K. Such adjustments for gains and losses are primarily driven by events and circumstances beyond the Company's control, including changes in interest rates, the performance of the financial markets and mortality assumptions. Service costs for plans in active accrual are included in operating expenses.

Derivatives And Hedging Activit

Derivatives And Hedging Activities	3 Months Ended
	Apr. 04, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivatives and Hedging Activities	Derivatives and Hedging Activities The Company uses derivative instruments as part of its risk management strategy only, and includes derivatives utilized as economic hedges that are not designated as hedging instruments. By nature, all financial instruments involve market and credit risks. The Company enters into derivative instruments with major investment grade financial institutions and has policies to monitor the credit risk of those counterparties. The Company does not enter into derivative contracts for trading or other speculative purposes, nor does the Company use leveraged financial instruments. Approximately 70% of the Company’s business is conducted outside of the United States, generally in foreign currencies. As a result, fluctuations in foreign currency exchange rates can increase the costs of financing, investing and operating the business. In the ordinary course of business, the Company enters into foreign exchange contracts for periods consistent with its committed exposures to mitigate the effect of foreign currency movements on transactions denominated in foreign currencies. The intent of these economic hedges is to offset gains and losses that occur on the underlying exposures from these currencies, with gains and losses resulting from the forward currency contracts that hedge these exposures. Transactions covered by hedge contracts include intercompany and third-party receivables and payables. The contracts are primarily in European and Asian currencies, have maturities that do not exceed 12 months, have no cash requirements until maturity, and are recorded at fair value on the Company’s condensed consolidated balance sheets. The unrealized gains and losses on the Company’s foreign currency contracts are recognized immediately in interest and other expense, net. The cash flows related to the settlement of these hedges are included in cash flows from operating activities within the Company’s condensed consolidated statement of cash flows. Principal hedged currencies include the British Pound, Euro, Indian Rupee, Singapore Dollar and Swedish Krona. The Company held forward foreign exchange contracts, designated as economic hedges, with U.S. dollar equivalent notional amounts totaling $969.5 million, $808.0 million and $272.4 million at April 4, 2021, January 3, 2021 and April 5, 2020, respectively, and the fair value of these foreign currency derivative contracts was insignificant. The gains and losses realized on these foreign currency derivative contracts are not material. The duration of these contracts was generally 30 days or less during each of the three months ended April 4, 2021 and April 5, 2020. In addition, in connection with certain intercompany loan agreements utilized to finance its acquisitions and stock repurchase program, the Company enters into forward foreign exchange contracts intended to hedge movements in foreign exchange rates prior to settlement of such intercompany loans denominated in foreign currencies. The Company records these hedges at fair value on the Company’s condensed consolidated balance sheets. The unrealized gains and losses on these hedges, as well as the gains and losses associated with the remeasurement of the intercompany loans, are recognized immediately in interest and other expense, net. The cash flows related to the settlement of these hedges are included in cash flows from financing activities within the Company’s condensed consolidated statement of cash flows. The outstanding forward exchange contracts designated as economic hedges, which were intended to hedge movements in foreign exchange rates prior to the settlement of certain intercompany loan agreements included combined U.S. Dollar notional amounts of $1,309.0 million as of April 4, 2021, combined Euro notional amounts of €33.4 million and combined U.S. Dollar notional amounts of $499.0 million as of January 3, 2021, and combined Euro notional amounts of €108.0 million and combined U.S. Dollar notional amounts of $138.9 million as of April 5, 2020. The net gains and losses on these derivatives, combined with the gains and losses on the remeasurement of the hedged intercompany loans were not material for each of the three months ended April 4, 2021 and April 5, 2020. The Company received $6.0 million and $8.7 million during the three months ended April 4, 2021 and April 5, 2020, respectively, from the settlement of these hedges. During fiscal year 2018, the Company designated a portion of the 2026 Notes to hedge its investments in certain foreign subsidiaries. Unrealized translation adjustments from a portion of the 2026 Notes were included in the foreign currency translation component of accumulated other comprehensive income ("AOCI"), which offsets translation adjustments on the underlying net assets of foreign subsidiaries. The cumulative translation gains or losses will remain in AOCI until the foreign subsidiaries are liquidated or sold. As of April 4, 2021, the total notional amount of the 2026 Notes that was designated to hedge investments in foreign subsidiaries was €299.7 million. The unrealized foreign exchange gains recorded in AOCI related to the net investment hedge were $21.6 million and $21.0 million for the three months ended April 4, 2021 and April 5, 2020, respectively. During fiscal year 2019, the Company entered into a cross-currency swap designated as a net investment hedge to hedge the Euro currency exposure of the Company’s net investment in certain foreign subsidiaries. This agreement is a contract to exchange fixed-rate payments in one currency for fixed-rate payments in another currency. Changes in the fair value of this swap are recorded in equity as a component of AOCI in the same manner as foreign currency translation adjustments. In assessing the effectiveness of this hedge, the Company uses a method based on changes in spot rates to measure the impact of the foreign currency exchange rate fluctuations on both its foreign subsidiary net investment and the related swap. Under this method, changes in the fair value of the hedging instrument other than those due to changes in the spot rate are initially recorded in AOCI as a translation adjustment, and then are amortized into other (income) expense, net in the condensed consolidated statement of operations using a systematic and rational method over the instrument’s term. Changes in the fair value associated with the effective portion (i.e. those changes due to the spot rate) are recorded in AOCI as a translation adjustment and are released and recognized in earnings only upon the sale or liquidation of the hedged net investment. The cross-currency swap has an initial notional value of €197.4 million, or $220.0 million, and matures on November 15, 2021. Interest on the cross-currency swap is payable semi-annually, in Euro, on May 15th and November 15th of each year based on the Euro notional value and a fixed rate of 2.47%. The Company receives interest in U.S. dollars on May 15th and November 15th of each year based on the U.S. dollar equivalent of the Euro notional value and a fixed rate of 5.00%. At April 4, 2021, the fair value of the cross-currency swap was $(10.1) million, which was recorded in AOCI. The unrealized foreign exchange (losses) gains recorded in AOCI related to the cross-currency swap were $(10.1) million and $8.9 million for the three months ended April 4, 2021 and April 5, 2020, respectively. During fiscal year 2020, the Company entered into a forward foreign exchange contracts, designated as cash flow hedges, to hedge the 2021 Notes. The effective portion of the gain or loss of the cash flow hedges will be reported as a component of other comprehensive income and reclassified into earnings in the same period during which the hedged transaction affects earnings. As of April 4, 2021, the total notional amount of the forward foreign exchange contracts that were designated as cash flow hedges was €300.0 million. The unrealized foreign exchange gains recorded in earnings related to the cash flow hedges were $13.6 million for the three months ended April 4, 2021. During fiscal year 2021, the Company entered into forward foreign exchange contracts, designated as a cash flow hedge, to hedge a portion of the 2026 Notes. The effective portion of the gain or loss of the cash flow hedge will be reported as a component of other comprehensive income and reclassified into earnings in the same period during which the hedged transaction affects earnings. As of April 4, 2021, the total notional amount of the forward foreign exchange contracts that were designated as cash flow hedges was €197.4 million. The unrealized foreign exchange loss recorded in earnings related to the cash flow hedge was $0.9 million for the three months ended April 4, 2021. The Company does not expect any material net pre-tax gains or losses to be reclassified from accumulated other comprehensive loss into interest and other expense, net within the next twelve months.

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Apr. 04, 2021
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash equivalents, derivatives, marketable securities and accounts receivable. The Company believes it had no significant concentrations of credit risk as of April 4, 2021. The Company uses the market approach technique to value its financial instruments and there were no changes in valuation techniques during the three months ended April 4, 2021. The Company’s financial assets and liabilities carried at fair value are primarily comprised of marketable securities, derivative contracts used to hedge the Company’s currency risk, and acquisition-related contingent consideration. The Company has not elected to measure any additional financial instruments or other items at fair value. Valuation Hierarchy: The following summarizes the three levels of inputs required to measure fair value. For Level 1 inputs, the Company utilizes quoted market prices as these instruments have active markets. For Level 2 inputs, the Company utilizes quoted market prices in markets that are not active, broker or dealer quotations, or utilizes alternative pricing sources with reasonable levels of price transparency. For Level 3 inputs, the Company utilizes unobservable inputs based on the best information available, including estimates by management primarily based on information provided by third-party fund managers, independent brokerage firms and insurance companies. A financial asset’s or liability’s classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement. In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The following tables show the assets and liabilities carried at fair value measured on a recurring basis as of April 4, 2021 and January 3, 2021 classified in one of the three classifications described above: Fair Value Measurements at April 4, 2021 Using: Total Carrying Value at April 4, 2021 Quoted Prices in Significant Other Significant (In thousands) Marketable securities $ 41,531 $ 41,531 $ — $ — Foreign exchange derivative assets 17,840 — 17,840 — Foreign exchange derivative liabilities (18,561) — (18,561) — Contingent consideration (3,124) — — (3,124) Fair Value Measurements at January 3, 2021 Using: Total Carrying Value at January 3, 2021 Quoted Prices in Significant Other Significant (In thousands) Marketable securities $ 2,154 $ 2,154 $ — $ — Foreign exchange derivative assets 31,248 — 31,248 — Foreign exchange derivative liabilities (21,413) — (21,413) — Contingent consideration (2,953) — — (2,953) Level 1 and Level 2 Valuation Techniques: The Company’s Level 1 and Level 2 assets and liabilities are comprised of investments in equity and fixed-income securities as well as derivative contracts. For financial assets and liabilities that utilize Level 1 and Level 2 inputs, the Company utilizes both direct and indirect observable price quotes, including common stock price quotes, foreign exchange forward prices and bank price quotes. Below is a summary of valuation techniques for Level 1 and Level 2 financial assets and liabilities. Marketable securities: Include equity and fixed-income securities measured at fair value using the quoted market prices in active markets at the reporting date. Foreign exchange derivative assets and liabilities: Include foreign exchange derivative contracts that are valued using quoted forward foreign exchange prices at the reporting date. The Company’s foreign exchange derivative contracts are subject to master netting arrangements that allow the Company and its counterparties to net settle amounts owed to each other. Derivative assets and liabilities that can be net settled under these arrangements have been presented in the Company's condensed consolidated balance sheet on a net basis and are recorded in other assets. As of both April 4, 2021 and January 3, 2021, none of the master netting arrangements involved collateral. Level 3 Valuation Techniques: The Company’s Level 3 liabilities are comprised of contingent consideration related to acquisitions. For liabilities that utilize Level 3 inputs, the Company uses significant unobservable inputs. Below is a summary of valuation techniques for Level 3 liabilities. Contingent consideration: Contingent consideration is measured at fair value at the acquisition date using projected milestone dates, discount rates, probabilities of success and projected revenues (for revenue-based considerations). Projected risk-adjusted contingent payments are discounted back to the current period using a discounted cash flow model. The fair values of contingent consideration are calculated on a quarterly basis based on a collaborative effort of the Company’s operations, finance and accounting groups, as appropriate. Potential valuation adjustments are made as additional information becomes available, including the progress towards achieving the revenue targets as compared to initial projections, with the impact of such adjustments being recorded in the Company's consolidated statements of operations. As of April 4, 2021, the Company may have to pay contingent consideration, related to acquisitions with open contingency periods, of up to $7.3 million. The expected maximum earnout period for the acquisitions with open contingency periods does not exceed 1.8 years from April 4, 2021, and the remaining weighted average expected earnout period at April 4, 2021 was 1.1 years. A reconciliation of the beginning and ending Level 3 net liabilities for contingent consideration is as follows: Three Months Ended April 4, April 5, (In thousands) Balance at beginning of period $ (2,953) $ (35,481) Amounts paid and foreign currency translation 69 379 Change in fair value (included within selling, general and administrative expenses) (240) 12,325 Balance at end of period $ (3,124) $ (22,777) The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximate fair value due to the short-term maturities of these assets and liabilities. If measured at fair value, cash and cash equivalents would be classified as Level 1. The Company's outstanding senior unsecured notes had a fair value of $2,710.0 million and a carrying value of $2,567.5 million as of April 4, 2021. The Company's outstanding senior unsecured notes had a fair value of $1,984.3 million and a carrying value of $1,811.5 million as of January 3, 2021. The fair values of the outstanding senior unsecured notes were estimated using market quotes from brokers and were based on current rates offered for similar debt, which are Level 2 measurements. The Company’s other debt facilities, including the senior revolving credit facility, had an aggregate carrying value of $12.7 million and $179.1 million as of April 4, 2021 and January 3, 2021, respectively. As of April 4, 2021, these consisted of bank loans in the aggregate amount of $12.7 million bearing fixed interest rates between 1.1% and 8.9% and a bank loan in the amount of $49,400 bearing a variable interest rate based on the Euribor rate plus a margin of 1.5%. The Company had no change in credit standing during the first three months of fiscal year 2021. Consequently, the carrying value approximates fair value and were classified as Level 2. As of April 4, 2021, there has not been any significant impact to the fair value of the Company’s derivative liabilities due to credit risk. Similarly, there has not been any significant adverse impact to the Company’s derivative assets based on the evaluation of its counterparties’ credit risks.

Contingencies

Contingencies	3 Months Ended
	Apr. 04, 2021
Commitments and Contingencies Disclosure [Abstract]
Contingencies	ContingenciesThe Company is conducting a number of environmental investigations and remedial actions at current and former locations of the Company and, along with other companies, has been named a potentially responsible party (“PRP”) for certain waste disposal sites. The Company accrues for environmental issues in the accounting period that the Company’s responsibility is established and when the cost can be reasonably estimated. The Company has accrued $12.1 million and $12.9 million as of April 4, 2021 and January 3, 2021, respectively, which represents its management’s estimate of the cost of the remediation of known environmental matters and does not include any potential liability for related personal injury or property damage claims. These amounts were included in accrued expenses and other current liabilities. The Company's environmental accrual is not discounted and does not reflect the recovery of any material amounts through insurance or indemnification arrangements. The cost estimates are subject to a number of variables, including the stage of the environmental investigations, the magnitude of the possible contamination, the nature of the potential remedies, possible joint and several liability, the time period over which remediation may occur, and the possible effects of changing laws and regulations. For sites where the Company has been named a PRP, management does not currently anticipate any additional liability to result from the inability of other significant named parties to contribute. The Company expects that the majority of such accrued amounts could be paid out over a period of up to ten years. As assessment and remediation activities progress at each individual site, these liabilities are reviewed and adjusted to reflect additional information as it becomes available. There have been no environmental problems to date that have had, or are expected to have, a material adverse effect on the Company’s condensed consolidated financial statements. While it is possible that a loss exceeding the amounts recorded in the condensed consolidated financial statements may be incurred, the potential exposure is not expected to be materially different from those amounts recorded. The Company is subject to various claims, legal proceedings and investigations covering a wide range of matters that arise in the ordinary course of its business activities. Although the Company has established accruals for potential losses that it believes are probable and reasonably estimable, in the opinion of the Company’s management, based on its review of the information available at this time, the total cost of resolving these contingencies at April 4, 2021 would not have a material adverse effect on the Company’s condensed consolidated financial statements. However, each of these matters is subject to uncertainties, and it is possible that some of these matters may be resolved unfavorably to the Company.

Basis of Presentation (Policies

Basis of Presentation (Policies)	3 Months Ended
	Apr. 04, 2021
Accounting Policies [Abstract]
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Adopted and Issued Accounting Pronouncements: From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (the "FASB") and are adopted by the Company as of the specified effective dates. Unless otherwise discussed, such pronouncements did not have or will not have a significant impact on the Company’s consolidated financial position, results of operations and cash flows or do not apply to the Company’s operations. In December 2019, the FASB issued Accounting Standards Update No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes ("ASU 2019-12"). ASU 2019-12 eliminates certain exceptions and adds guidance to reduce complexity in accounting for income taxes. Specifically, this guidance: (1) removes the intraperiod tax allocation exception to the incremental approach; (2) removes the ownership changes in investments exception in determining when a deferred tax liability is recognized after an investor in a foreign entity transitions to or from the equity method of accounting and applies this provision on a modified retrospective basis through a cumulative-effect adjustment to retained earnings at the beginning of the period of adoption; and (3) removes the exception to using the general methodology for calculating income taxes in an interim period when a year-to-date loss exceeds the anticipated loss for the year. ASU 2019-12 also simplifies accounting principles by making other changes, including requiring an entity to: (1) evaluate whether a step-up in tax basis of goodwill relates to a business combination or a separate transaction; (2) make a policy election to not allocate consolidated income taxes when a member of a consolidated tax return is not subject to income tax and to apply this provision retrospectively to all periods presented; and (3) recognize a franchise tax (or similar tax) that is partially based on income as an income-based tax and apply this provision either retrospectively for all periods presented or on a modified retrospective basis through a cumulative-effect adjustment to retained earnings as of the beginning of the period of adoption. The provisions of this guidance (except as specifically mentioned above) are to be applied prospectively upon their effective date. ASU 2019-12 is effective for annual reporting periods beginning after December 15, 2020, and interim p eriods within those years. In accordance with ASU 2019-12, the Company adopted the guidance beginning on January 4, 2021. The adoption did not have a material impact on the Company's consolidated financial position, results of operations and cash flows.

Revenue (Tables)

Revenue (Tables)	3 Months Ended
	Apr. 04, 2021
Disaggregation of Revenue [Line Items]
Disaggregation of Revenue [Table Text Block]	In the following tables, revenue is disaggregated by primary geographical markets, primary end-markets and timing of revenue recognition. The tables also include a reconciliation of the disaggregated revenue with the reportable segments' revenue. Reportable Segments Three Months Ended April 4, 2021 April 5, 2020 Discovery & Analytical Solutions Diagnostics Total Discovery & Analytical Solutions Diagnostics Total (In thousands) Primary geographical markets Americas $ 175,115 $ 400,927 $ 576,042 $ 169,116 $ 105,157 $ 274,273 Europe 135,458 311,743 447,201 118,657 81,599 200,256 Asia 144,036 140,410 284,446 110,622 67,245 177,867 $ 454,609 $ 853,080 $ 1,307,689 $ 398,395 $ 254,001 $ 652,396 Primary end-markets Diagnostics $ — $ 853,080 $ 853,080 $ — $ 254,001 $ 254,001 Life sciences 277,201 — 277,201 245,733 — 245,733 Applied markets 177,408 — 177,408 152,662 — 152,662 $ 454,609 $ 853,080 $ 1,307,689 $ 398,395 $ 254,001 $ 652,396 Timing of revenue recognition Products and services transferred at a point in time $ 326,662 $ 615,106 $ 941,768 $ 267,907 $ 231,653 $ 499,560 Services transferred over time 127,947 237,974 365,921 130,488 22,348 152,836 $ 454,609 $ 853,080 $ 1,307,689 $ 398,395 $ 254,001 $ 652,396

Business Combinations (Tables)

Business Combinations (Tables)	3 Months Ended
	Apr. 04, 2021
Business Acquisition [Line Items]
Schedule of Business Acquisitions, by Acquisition1 [Table Text Block]	The total purchase price for the acquisitions in fiscal year 2020 has been allocated to the estimated fair values of assets acquired and liabilities assumed as follows: Preliminary Horizon Other (In thousands) Fair value of business combination: Cash payments $ 399,005 $ 38,243 Other liability 396 1,263 Working capital and other adjustments — (384) Less: cash acquired (25,539) (1,300) Total $ 373,862 $ 37,822 Identifiable assets acquired and liabilities assumed: Current assets $ 29,762 $ 5,770 Property, plant and equipment 17,729 2,673 Other assets 17,743 371 Identifiable intangible assets: Core technology 60,000 5,730 Trade names 4,900 680 Customer relationships 97,600 10,923 Goodwill 202,071 16,016 Deferred taxes (22,651) (1,132) Deferred revenue (2,031) — Debt assumed — (29) Liabilities assumed (41,961) (3,180) Total $ 373,862 $ 37,822

Restructuring and Lease Charg_2

Restructuring and Lease Charges, Net (Tables)	3 Months Ended
	Apr. 04, 2021
Restructuring Cost and Reserve [Line Items]
Schedule of Restructuring Plan Activity [Table Text Block]	The following table summarizes the reductions in headcount, the initial restructuring or contract termination charges by reporting segment, and the dates by which payments were substantially completed, or the dates by which payments are expected to be substantially completed, for restructuring actions implemented during fiscal years 2021 and 2020 in continuing operations: Workforce Reductions Closure of Excess Facility Total (Expected) Date Payments Substantially Completed by Headcount Reduction Discovery & Analytical Solutions Diagnostics Discovery & Analytical Solutions Diagnostics Severance Excess Facility (In thousands, except headcount data) Q1 2021 Plan 77 $ 3,941 $ 1,615 $ — $ — $ 5,556 Q4 FY2021 — Q3 2020 Plan 23 2,080 901 — — 2,981 Q2 FY2021 — Q1 2020 Plan 32 2,312 1,134 92 682 4,220 Q4 FY2020 Q1 FY2022
Schedule of Restructuring Reserve by Type of Cost [Table Text Block]	The following table summarizes the Company's restructuring accrual balances and related activity by restructuring plan, as well as other accrual balances and related activity, during the three months ended April 4, 2021: Balance at January 3, 2021 2021 Charges 2021 Changes in Estimates, Net 2021 Amounts Paid Balance at April 4, 2021 (In thousands) Severance: Q1 2021 Plan $ — $ 5,556 $ — $ (917) $ 4,639 Q3 2020 Plan 1,167 — — (443) 724 Q1 2020 Plan 872 — — (268) 604 Facility: Q1 2020 Plan 394 — — (85) 309 Previous Plans 3,550 — — (106) 3,444 Restructuring 5,983 5,556 — (1,819) 9,720 Contract Termination 318 — 35 (15) 338 Other Costs 1,998 188 — (2,186) — Total Restructuring and Other Liabilities $ 8,299 $ 5,744 $ 35 $ (4,020) $ 10,058

Interest and Other Expense (I_2

Interest and Other Expense (Income), Net (Tables)	3 Months Ended
	Apr. 04, 2021
Other Income and Expenses [Abstract]
Interest and Other Expense (Income), Net	Interest and other expense, net, consisted of the following: Three Months Ended April 4, April 5, (In thousands) Interest income $ (411) $ (265) Interest expense 14,126 13,665 Change in fair value of financial securities (19,298) — Other income, net (7,123) (3,407) Total interest and other (income) expense, net $ (12,706) $ 9,993

Inventories, Net (Tables)

Inventories, Net (Tables)	3 Months Ended
	Apr. 04, 2021
Inventory Disclosure [Abstract]
Schedule of Net Inventories	Inventories as of April 4, 2021 and January 3, 2021 consisted of the following: April 4, January 3, (In thousands) Raw materials $ 196,712 $ 205,022 Work in progress 44,676 35,160 Finished goods 288,520 274,385 Total inventories $ 529,908 $ 514,567

Earnings Per Share (Tables)

Earnings Per Share (Tables)	3 Months Ended
	Apr. 04, 2021
Earnings Per Share [Abstract]
Schedule of Reconciliation of Number of Shares Utilized in Earnings Per Share Calculations	The following table reconciles the number of shares utilized in the earnings per share calculations: Three Months Ended April 4, April 5, (In thousands) Number of common shares—basic 112,028 111,121 Effect of dilutive securities: Stock options 359 480 Restricted stock awards 108 43 Number of common shares—diluted 112,495 111,644 Number of potentially dilutive securities excluded from calculation due to antidilutive impact 162 491

Industry Segment Information (T

Industry Segment Information (Tables)	3 Months Ended
	Apr. 04, 2021
Segment Reporting [Abstract]
Schedule of Sales and Operating Income by Operating Segment, Excluding Discontinued Operations	Revenue and operating income (loss) from continuing operations by operating segment are shown in the table below: Three Months Ended April 4, April 5, (In thousands) Discovery & Analytical Solutions Product revenue $ 267,255 $ 215,356 Service revenue 187,354 183,039 Total revenue 454,609 398,395 Operating income from continuing operations 42,947 28,513 Diagnostics Product revenue 544,297 210,173 Service revenue 308,783 43,828 Total revenue 853,080 254,001 Operating income from continuing operations 441,467 29,591 Corporate Operating loss from continuing operations (16,638) (13,422) Continuing Operations Product revenue 811,552 425,529 Service revenue 496,137 226,867 Total revenue 1,307,689 652,396 Operating income from continuing operations 467,776 44,682 Interest and other (income) expense, net (see Note 5) (12,706) 9,993 Income from continuing operations before income taxes $ 480,482 $ 34,689

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	3 Months Ended
	Apr. 04, 2021
Stockholders' Equity Note [Abstract]
Components of Accumulated Other Comprehensive Loss	The components of accumulated other comprehensive loss consisted of the following: April 4, January 3, (In thousands) Foreign currency translation adjustments, net of income taxes $ (103,242) $ (30,937) Unrecognized prior service costs, net of income taxes (747) (747) Unrealized net losses on securities, net of income taxes (183) (277) Accumulated other comprehensive loss $ (104,172) $ (31,961)

Stock Plans (Tables)

Stock Plans (Tables)	3 Months Ended
	Apr. 04, 2021
Share-based Payment Arrangement [Abstract]
Summary of Total Compensation Recognized Related to Outstanding Equity Awards	The following table summarizes total pre-tax compensation expense recognized related to the Company’s stock option grants, restricted stock awards, performance restricted stock units, performance units and stock awards, included in the Company’s condensed consolidated statements of operations for the three months ended April 4, 2021 and April 5, 2020: Three Months Ended April 4, April 5, (In thousands) Cost of revenue $ 396 $ 254 Research and development expenses 197 272 Selling, general and administrative expenses 4,564 2,524 Total stock-based compensation expense $ 5,157 $ 3,050 The total income tax benefit recognized in the condensed consolidated statements of operations for stock-based compensation was $4.1 million and $2.2 million for the three months ended April 4, 2021 and April 5, 2020, respectively. Stock-based compensation costs capitalized as part of inventory were $0.5 million and $0.3 million as of April 4, 2021 and April 5, 2020, respectively.
Weighted-Average Assumptions Used in the Black-Scholes Option Pricing Model	The Company’s weighted-average assumptions used in the Black-Scholes option pricing model were as follows: Three Months Ended April 4, April 5, Risk-free interest rate 0.6 % 0.9 % Expected dividend yield 0.2 % 0.3 % Expected term 5 years 5 years Expected stock volatility 27.3 % 23.8 %
Summary of Stock Option Activity	The following table summarizes stock option activity for the three months ended April 4, 2021: Number Weighted- Weighted-Average Total (In thousands) (In years) (In millions) Outstanding at January 3, 2021 961 $ 74.40 Granted 162 134.53 Exercised (96) 53.98 Forfeited (7) 88.54 Outstanding at April 4, 2021 1,020 $ 85.78 4.3 $ 46.2 Exercisable at April 4, 2021 640 $ 72.63 3.2 $ 36.7
Summary of Restricted Stock Award Activity	The following table summarizes restricted stock award activity for the three months ended April 4, 2021: Number of Weighted- (In thousands) Nonvested at January 3, 2021 296 $ 85.67 Granted 102 129.27 Vested (102) 83.16 Forfeited (5) 86.90 Nonvested at April 4, 2021 291 $ 101.83

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets, Net (Tables)	3 Months Ended
	Apr. 04, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Changes in the Carrying Amount of Goodwill	The changes in the carrying amount of goodwill for the three months ended April 4, 2021 were as follows: Discovery & Analytical Solutions Diagnostics Consolidated (In thousands) Balance at January 3, 2021 $ 1,755,887 $ 1,691,227 $ 3,447,114 Foreign currency translation (23,119) (22,268) (45,387) Acquisitions, earn-outs and other 1,326 280,737 282,063 Balance at April 4, 2021 $ 1,734,094 $ 1,949,696 $ 3,683,790
Identifiable Intangible Asset Balances	Identifiable intangible asset balances by category were as follows: April 4, January 3, (In thousands) Patents $ 30,843 $ 30,855 Less: Accumulated amortization (28,484) (28,440) Net patents 2,359 2,415 Trade names and trademarks 120,444 98,661 Less: Accumulated amortization (49,853) (48,806) Net trade names and trademarks 70,591 49,855 Licenses 58,705 58,700 Less: Accumulated amortization (53,005) (52,452) Net licenses 5,700 6,248 Core technology 936,682 789,799 Less: Accumulated amortization (411,558) (398,992) Net core technology 525,124 390,807 Customer relationships 1,334,715 1,357,660 Less: Accumulated amortization (546,783) (522,820) Net customer relationships 787,932 834,840 In-process research and development 10,966 10,944 Net amortizable intangible assets 1,402,672 1,295,109 Non-amortizing intangible asset: Trade name 70,584 70,584 Total $ 1,473,256 $ 1,365,693

Warranty Reserves (Tables)

Warranty Reserves (Tables)	3 Months Ended
	Apr. 04, 2021
Product Warranties Disclosures [Abstract]
Warranty Reserve Activity	A summary of warranty reserve activity is as follows: Three Months Ended April 4, April 5, (In thousands) Balance at beginning of period $ 12,073 $ 8,812 Provision charged to income 3,691 2,712 Payments (6,182) (3,266) Adjustments to previously provided warranties, net 2,455 1,052 Foreign currency translation and acquisitions (190) (269) Balance at end of period $ 11,847 $ 9,041

Employee Benefit Plans (Tables)

Employee Benefit Plans (Tables)	3 Months Ended
	Apr. 04, 2021
Retirement Benefits [Abstract]
Components of Net Periodic Benefit Cost (Credit)	The following table summarizes the components of net periodic pension credit for the Company’s various defined benefit employee pension and postretirement plans: Defined Benefit Postretirement Three Months Ended April 4, April 5, April 4, April 5, (In thousands) Service and administrative costs $ 1,334 $ 1,907 $ 14 $ 18 Interest cost 2,377 3,144 17 24 Expected return on plan assets (6,127) (5,384) (397) (347) Net periodic pension credit $ (2,416) $ (333) $ (366) $ (305)

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Apr. 04, 2021
Fair Value Disclosures [Abstract]
Assets and Liabilities Carried at Fair Value Measured on a Recurring Basis	The following tables show the assets and liabilities carried at fair value measured on a recurring basis as of April 4, 2021 and January 3, 2021 classified in one of the three classifications described above: Fair Value Measurements at April 4, 2021 Using: Total Carrying Value at April 4, 2021 Quoted Prices in Significant Other Significant (In thousands) Marketable securities $ 41,531 $ 41,531 $ — $ — Foreign exchange derivative assets 17,840 — 17,840 — Foreign exchange derivative liabilities (18,561) — (18,561) — Contingent consideration (3,124) — — (3,124) Fair Value Measurements at January 3, 2021 Using: Total Carrying Value at January 3, 2021 Quoted Prices in Significant Other Significant (In thousands) Marketable securities $ 2,154 $ 2,154 $ — $ — Foreign exchange derivative assets 31,248 — 31,248 — Foreign exchange derivative liabilities (21,413) — (21,413) — Contingent consideration (2,953) — — (2,953)
Reconciliation of Beginning and Ending Level 3 Net Liabilities	A reconciliation of the beginning and ending Level 3 net liabilities for contingent consideration is as follows: Three Months Ended April 4, April 5, (In thousands) Balance at beginning of period $ (2,953) $ (35,481) Amounts paid and foreign currency translation 69 379 Change in fair value (included within selling, general and administrative expenses) (240) 12,325 Balance at end of period $ (3,124) $ (22,777)

Basis of Presentation (Basis of

Basis of Presentation (Basis of Presentation) (Details) - USD ($) $ in Thousands	3 Months Ended
	Apr. 04, 2021	Apr. 05, 2020	Jan. 03, 2021
Basis of Presentation [Line Items]
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	$ (6,849)	$ (10,169)
Operating Lease, Right-of-Use Asset	$ 213,306		$ 207,236
Accounting Standards Update 2016-02 [Member]
Basis of Presentation [Line Items]
Cumulative Effect of New Accounting Pronouncement in Period of Adoption		$ (1,328)

Revenue (Details)

Revenue (Details) - USD ($) $ in Thousands	3 Months Ended
	Apr. 04, 2021	Apr. 05, 2020	Jan. 03, 2021
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	$ 1,307,689	$ 652,396
Contract with Customer, Asset and Liability [Abstract]
Contract with Customer, Asset, Net, Current	50,200		$ 59,500
Contract with Customer, Liability, Current	221,000		$ 238,100
Contract with Customer, Liability, Revenue Recognized	(38,000)
Unbilled Receivables Transferred To Accounts Receivables	(37,800)
Contract with Customer, Liability, Increase (Decrease)	20,900
Contract with Customer, Asset, Increase (Decrease)	28,500
Transferred at Point in Time [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	941,768	499,560
Transferred over Time [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	365,921	152,836
Americas [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	576,042	274,273
Europe [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	447,201	200,256
Asia [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	284,446	177,867
Discovery & Analytical Solutions [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	454,609	398,395
Discovery & Analytical Solutions [Member] | Transferred at Point in Time [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	326,662	267,907
Discovery & Analytical Solutions [Member] | Transferred over Time [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	127,947	130,488
Discovery & Analytical Solutions [Member] | Americas [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	175,115	169,116
Discovery & Analytical Solutions [Member] | Europe [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	135,458	118,657
Discovery & Analytical Solutions [Member] | Asia [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	144,036	110,622
Diagnostics [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	853,080	254,001
Diagnostics [Member] | Customer Concentration Risk [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	205,600
Diagnostics [Member] | Transferred at Point in Time [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	615,106	231,653
Diagnostics [Member] | Transferred over Time [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	237,974	22,348
Diagnostics [Member] | Americas [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	400,927	105,157
Diagnostics [Member] | Europe [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	311,743	81,599
Diagnostics [Member] | Asia [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	140,410	67,245
Life Sciences [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	277,201	245,733
Life Sciences [Member] | Discovery & Analytical Solutions [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	277,201	245,733
Life Sciences [Member] | Diagnostics [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	0	0
Diagnostics [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	853,080	254,001
Diagnostics [Member] | Discovery & Analytical Solutions [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	0	0
Diagnostics [Member] | Diagnostics [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	853,080	254,001
Applied Markets [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	177,408	152,662
Applied Markets [Member] | Discovery & Analytical Solutions [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	177,408	152,662
Applied Markets [Member] | Diagnostics [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	$ 0	$ 0

Changes in Accounting Policies

Changes in Accounting Policies (Details) - USD ($) $ in Thousands	3 Months Ended
	Apr. 04, 2021	Apr. 05, 2020	Jan. 03, 2021	Dec. 29, 2019
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Cost of Goods and Services Sold	$ (522,543)	$ (344,373)
Selling, general and administrative expenses	251,410	208,569
Research and development expenses	60,216	48,914
Restructuring and other costs, net	5,744	5,858
Operating income (loss) from continuing operations	467,776	44,682
Nonoperating Income (Expense)	(12,706)	9,993
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest	480,482	34,689
Provision for income taxes	101,139	974
Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent	379,343	33,715
Loss on disposition of discontinued operations before income taxes	0	0
Cash and cash equivalents	988,234	195,146	$ 402,036
Accounts receivable, net	(978,598)		(1,155,109)
Inventories	529,908		514,567
Other current assets	(177,831)		(167,208)
Property, Plant and Equipment, Net	371,102		368,304
Intangible assets, net	1,473,256		1,365,693
Goodwill	3,683,790		3,447,114
Other assets, net	346,700		333,048
Assets	(8,762,725)		(7,960,315)
Current portion of long-term debt	358,435		380,948
Accounts payable	339,326		327,325
Accrued expenses and other current liabilities			4,700
Accrued expenses and other current liabilities	822,749		943,916
Long-term debt	2,219,670		1,609,701
Long-term liabilities	827,636		774,531
Liabilities	4,760,420		4,224,823
Preferred Stock, Value, Issued	0		0
Common Stock, Value, Issued	112,066		112,090
Capital in excess of par value	115,690		148,101
Retained earnings	3,878,721		3,507,262
Accumulated other comprehensive loss	(104,172)		(31,961)
Stockholders' Equity Attributable to Parent	4,002,305	2,759,746	3,735,492	$ 2,813,824
Liabilities and Equity	(8,762,725)		$ (7,960,315)
Discontinued Operation, Tax Effect of Discontinued Operation	38	50
Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest	(38)	(50)
Net income	$ 379,305	$ 33,665

Business Combinations (Narrativ

Business Combinations (Narrative) (Details)	3 Months Ended		12 Months Ended
	Apr. 04, 2021USD ($)employees	Apr. 05, 2020USD ($)	Jan. 03, 2021USD ($)employees	Dec. 29, 2019USD ($)
Business Acquisition [Line Items]
Number of Years in Measurement Period from Acquisition Date to Change Underlying Assumptions	1 year
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	$ 7,300,000
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value	$ 3,124,000	$ 22,777,000	$ 2,953,000	$ 35,481,000
Business Combination, Contingent Consideration Arrangements, Maximum Period	1 year 9 months 18 days
Business Combination, Contingent Consideration Arrangements, Weighted Average Period	1 year 1 month 6 days
Total transaction costs	$ 4,400,000	12,400,000
Business Combination, Contingent Consideration Arrangements, Description	Contingent consideration is measured at fair value at the acquisition date, based on the probability that revenue thresholds or product development milestones will be achieved during the earnout period, with changes in the fair value after the acquisition date affecting earnings to the extent it is to be settled in cash.
Goodwill	$ 3,683,790,000		3,447,114,000
Business Combination, Contingent Consideration, Liability, Current	3,000,000		2,900,000
Business Combination, Contingent Consideration, Liability, Noncurrent	100,000		100,000
Foreign Currency Transaction Gain (Loss), before Tax	(1,300,000)	(7,900,000)
Interest Expense	14,126,000	13,665,000
Business Combination, Contingent Consideration, Liability	$ 3,100,000		$ 3,000,000
Fiscal Year 2021 Acquisitions [Member]
Business Acquisition [Line Items]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	11 years 1 month 6 days
Oxford Immunotec [Member]
Business Acquisition [Line Items]
Business Combination, Consideration Transferred	$ 441,279,000
Cash Acquired	(149,586,000)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets	25,815,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment	12,404,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets	$ 10,553,000
Entity Number of Employees | employees	275
Cash paid to the shareholders	$ 590,865,000
Business Combination, Consideration Transferred, Liabilities Incurred	0
Goodwill	280,944,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt	35,532,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net	441,279,000
Foreign Currency Transaction Gain (Loss), before Tax	(5,400,000)
Interest Expense	200,000
Fiscal Year 2021 Other Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Consideration Transferred	2,500,000
Cash Acquired	0
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets	25,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment	65,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets	0
Cash paid to the shareholders	2,250,000
Business Combination, Consideration Transferred, Liabilities Incurred	250,000
Goodwill	0
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt	0
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net	2,500,000
Fiscal Year 2020 Acquisitions [Member]
Business Acquisition [Line Items]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life			11 years
Horizon Discovery Group plc [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost Of Acquired Entity, Working Capital Adjustments			$ 0
Business Combination, Consideration Transferred			373,862,000
Cash Acquired			(25,539,000)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets			29,762,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment			17,729,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets			$ 17,743,000
Entity Number of Employees | employees			400
Cash paid to the shareholders			$ 399,005,000
Business Combination, Consideration Transferred, Liabilities Incurred			396,000
Goodwill			202,071,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt			41,961,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net			373,862,000
Shandong Meizheng [Member]
Business Acquisition [Line Items]
Compensation Expense, Excluding Cost of Good and Service Sold	5,400,000	$ 12,300,000
Fiscal Year 2020 Other Acquisitions
Business Acquisition [Line Items]
Business Acquisition, Cost Of Acquired Entity, Working Capital Adjustments			384,000
Business Combination, Consideration Transferred			37,822,000
Cash Acquired			(1,300,000)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets			5,770,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment			2,673,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets			371,000
Cash paid to the shareholders			38,243,000
Business Combination, Consideration Transferred, Liabilities Incurred			1,263,000
Goodwill			16,016,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt			3,180,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net			37,822,000
Diagnostics [Member]
Business Acquisition [Line Items]
Goodwill	1,949,696,000		1,691,227,000
Discovery & Analytical Solutions [Member]
Business Acquisition [Line Items]
Goodwill	1,734,094,000		1,755,887,000
Core Technology [Member] | Oxford Immunotec [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	150,000,000
Core Technology [Member] | Fiscal Year 2021 Other Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	2,410,000
Core Technology [Member] | Horizon Discovery Group plc [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles			60,000,000
Core Technology [Member] | Fiscal Year 2020 Other Acquisitions
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles			5,730,000
Customer Relationships [Member] | Oxford Immunotec [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	6,800,000
Customer Relationships [Member] | Fiscal Year 2021 Other Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	0
Customer Relationships [Member] | Horizon Discovery Group plc [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles			97,600,000
Customer Relationships [Member] | Fiscal Year 2020 Other Acquisitions
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles			10,923,000
Trade Names [Member] | Oxford Immunotec [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	23,800,000
Trade Names [Member] | Fiscal Year 2021 Other Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	0
Trade Names [Member] | Horizon Discovery Group plc [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles			4,900,000
Trade Names [Member] | Fiscal Year 2020 Other Acquisitions
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles			680,000
United States of America, Dollars | Fiscal Year 2021 Acquisitions [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments	593,400,000
United States of America, Dollars | Oxford Immunotec [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments	590,900,000
United States of America, Dollars | Fiscal Year 2021 Other Acquisitions [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments	$ 2,500,000
United States of America, Dollars | Fiscal Year 2020 Acquisitions [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments			438,700,000
United States of America, Dollars | Horizon Discovery Group plc [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments			399,400,000
United States of America, Dollars | Fiscal Year 2020 Other Acquisitions
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments			39,300,000
United Kingdom, Pounds | Horizon Discovery Group plc [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments			$ 296,000,000

Business Combinations (Fair Val

Business Combinations (Fair Values of the Business Combinations and Allocations for the Acquisitions Completed) (Details) - USD ($)	3 Months Ended	12 Months Ended
	Apr. 04, 2021	Jan. 03, 2021
Business Acquisition [Line Items]
Goodwill	$ 3,683,790,000	$ 3,447,114,000
Oxford Immunotec [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid	590,865,000
Business Combination, Consideration Transferred, Liabilities Incurred	0
Cash Acquired	(149,586,000)
Business Combination, Consideration Transferred	441,279,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets	25,815,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment	12,404,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets	10,553,000
Goodwill	280,944,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities, Total	(33,072,000)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue	(102,000)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities	(331,000)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt	(35,532,000)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net	441,279,000
Fiscal Year 2021 Other Acquisitions [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid	2,250,000
Business Combination, Consideration Transferred, Liabilities Incurred	250,000
Cash Acquired	0
Business Combination, Consideration Transferred	2,500,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets	25,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment	65,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets	0
Goodwill	0
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities, Total	0
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue	0
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities	0
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt	0
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net	2,500,000
Fiscal Year 2020 Other Acquisitions
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid		38,243,000
Business Combination, Consideration Transferred, Liabilities Incurred		1,263,000
Business Acquisition, Cost Of Acquired Entity, Working Capital Adjustments		384,000
Cash Acquired		(1,300,000)
Business Combination, Consideration Transferred		37,822,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets		5,770,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment		2,673,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets		371,000
Goodwill		16,016,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities, Total		(1,132,000)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue		0
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities		(29,000)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt		(3,180,000)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net		37,822,000
Horizon Discovery Group plc [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid		399,005,000
Business Combination, Consideration Transferred, Liabilities Incurred		396,000
Business Acquisition, Cost Of Acquired Entity, Working Capital Adjustments		0
Cash Acquired		(25,539,000)
Business Combination, Consideration Transferred		373,862,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets		29,762,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment		17,729,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets		17,743,000
Goodwill		202,071,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities, Total		(22,651,000)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue		(2,031,000)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities		0
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt		(41,961,000)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net		373,862,000
Core Technology [Member] | Oxford Immunotec [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	150,000,000
Core Technology [Member] | Fiscal Year 2021 Other Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	2,410,000
Core Technology [Member] | Fiscal Year 2020 Other Acquisitions
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles		5,730,000
Core Technology [Member] | Horizon Discovery Group plc [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles		60,000,000
Trade Names [Member] | Oxford Immunotec [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	23,800,000
Trade Names [Member] | Fiscal Year 2021 Other Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	0
Trade Names [Member] | Fiscal Year 2020 Other Acquisitions
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles		680,000
Trade Names [Member] | Horizon Discovery Group plc [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles		4,900,000
Customer Relationships [Member] | Oxford Immunotec [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	6,800,000
Customer Relationships [Member] | Fiscal Year 2021 Other Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	0
Customer Relationships [Member] | Fiscal Year 2020 Other Acquisitions
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles		10,923,000
Customer Relationships [Member] | Horizon Discovery Group plc [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles		97,600,000
License | Fiscal Year 2021 Other Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles
Diagnostics [Member]
Business Acquisition [Line Items]
Goodwill	1,949,696,000	1,691,227,000
Discovery & Analytical Solutions [Member]
Business Acquisition [Line Items]
Goodwill	$ 1,734,094,000	$ 1,755,887,000

Discontinued Operations (Narrat

Discontinued Operations (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended
	Apr. 04, 2021	Apr. 05, 2020
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest	$ (38)	$ (50)
Pre-tax gain (loss) on disposal of business unit	0	0
Discontinued Operation, Tax Effect of Discontinued Operation	$ 38	$ 50

Restructuring and Lease Charg_3

Restructuring and Lease Charges, Net (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended
	Apr. 04, 2021	Apr. 05, 2020	Jan. 03, 2021
Restructuring Cost and Reserve [Line Items]
Accrued restructuring and integration costs	$ 10,058		$ 8,299
Accrued expenses and other current liabilities			4,700
Restructuring Reserve, Accrual Adjustment	35
Restructuring and contract termination charges, net	5,744
Short-term accrued restructuring and other costs [Member]
Restructuring Cost and Reserve [Line Items]
Accrued expenses and other current liabilities	8,600
Accrued expenses and other current liabilities [Member]
Restructuring Cost and Reserve [Line Items]
Accrued expenses and other current liabilities			2,000
Operating lease liabilities [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve, Noncurrent	1,200		1,300
Operating lease right-of-use assets [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve, Noncurrent	200		300
Facility Relocation [Member]
Restructuring Cost and Reserve [Line Items]
Accrued restructuring and integration costs	0		$ 1,998
Restructuring Reserve, Accrual Adjustment	0
Restructuring and contract termination charges, net	188
Discovery & Analytical Solutions [Member] | Facility Relocation [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and contract termination charges, net	$ 200	$ 1,400

Restructuring and Lease Charg_4

Restructuring and Lease Charges, Net (Schedule of Initial Charges) (Details) $ in Thousands	3 Months Ended
	Apr. 04, 2021USD ($)employees	Oct. 04, 2020USD ($)employees	Apr. 05, 2020USD ($)employees	Jan. 03, 2021USD ($)
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	$ 10,058			$ 8,299
Restructuring and contract termination charges, net	5,744
Restructuring Reserve, Accrual Adjustment	35
Restructuring reserve Settled with Cash and Translation Adjustment	$ (4,020)
Q1 2021 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Number of Positions Eliminated | employees	77
Restructuring and contract termination charges, net	$ 5,556
Q3 2020 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Number of Positions Eliminated | employees		23
Restructuring and contract termination charges, net		$ 2,981
Q1 2020 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Number of Positions Eliminated | employees			32
Restructuring and contract termination charges, net			$ 4,220
Employee Severance [Member] | Q1 2021 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	4,639			0
Restructuring and contract termination charges, net	5,556
Restructuring Reserve, Accrual Adjustment	0
Restructuring reserve Settled with Cash and Translation Adjustment	(917)
Employee Severance [Member] | Q3 2020 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	724			1,167
Restructuring and contract termination charges, net	0
Restructuring Reserve, Accrual Adjustment	0
Restructuring reserve Settled with Cash and Translation Adjustment	(443)
Employee Severance [Member] | Q1 2020 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	604			872
Restructuring and contract termination charges, net	0
Restructuring Reserve, Accrual Adjustment	0
Restructuring reserve Settled with Cash and Translation Adjustment	(268)
Facility Closing [Member] | Q1 2020 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	309			394
Restructuring and contract termination charges, net	0
Restructuring Reserve, Accrual Adjustment	0
Restructuring reserve Settled with Cash and Translation Adjustment	(85)
Facility Relocation [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	0			$ 1,998
Restructuring and contract termination charges, net	188
Restructuring Reserve, Accrual Adjustment	0
Restructuring reserve Settled with Cash and Translation Adjustment	(2,186)
Diagnostics [Member] | Employee Severance [Member] | Q1 2021 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and contract termination charges, net	1,615	901
Diagnostics [Member] | Employee Severance [Member] | Q1 2020 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and contract termination charges, net			1,134
Diagnostics [Member] | Facility Closing [Member] | Q1 2021 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and contract termination charges, net	0
Diagnostics [Member] | Facility Closing [Member] | Q3 2020 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and contract termination charges, net		0
Diagnostics [Member] | Facility Closing [Member] | Q1 2020 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and contract termination charges, net			682
Discovery & Analytical Solutions [Member] | Employee Severance [Member] | Q1 2021 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and contract termination charges, net	3,941
Discovery & Analytical Solutions [Member] | Employee Severance [Member] | Q3 2020 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and contract termination charges, net		2,080
Discovery & Analytical Solutions [Member] | Employee Severance [Member] | Q1 2020 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and contract termination charges, net			2,312
Discovery & Analytical Solutions [Member] | Facility Closing [Member] | Q1 2021 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and contract termination charges, net	0
Discovery & Analytical Solutions [Member] | Facility Closing [Member] | Q3 2020 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and contract termination charges, net		$ 0
Discovery & Analytical Solutions [Member] | Facility Closing [Member] | Q1 2020 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and contract termination charges, net			92
Discovery & Analytical Solutions [Member] | Facility Relocation [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and contract termination charges, net	$ 200		$ 1,400

Restructuring and Lease Charg_5

Restructuring and Lease Charges, Net (Schedule of Restructuring Plan Activity) (Details) - USD ($) $ in Thousands	3 Months Ended
	Apr. 04, 2021	Oct. 04, 2020	Apr. 05, 2020
Restructuring Reserve [Roll Forward]
Balance at beginning of period	$ 8,299
Restructuring and contract termination charges, net	5,744
Restructuring Reserve, Accrual Adjustment	35
Restructuring reserve Settled with Cash and Translation Adjustment	(4,020)
Balance at end of period	10,058
Employee Severance and Facility Closing [Member]
Restructuring Reserve [Roll Forward]
Balance at beginning of period	5,983
Restructuring and contract termination charges, net	5,556
Restructuring Reserve, Accrual Adjustment	0
Restructuring reserve Settled with Cash and Translation Adjustment	(1,819)
Balance at end of period	9,720
Contract Termination [Member]
Restructuring Reserve [Roll Forward]
Balance at beginning of period	318
Restructuring and contract termination charges, net	0
Restructuring Reserve, Accrual Adjustment	35
Restructuring reserve Settled with Cash and Translation Adjustment	(15)
Balance at end of period	338
Facility Relocation [Member]
Restructuring Reserve [Roll Forward]
Balance at beginning of period	1,998
Restructuring and contract termination charges, net	188
Restructuring Reserve, Accrual Adjustment	0
Restructuring reserve Settled with Cash and Translation Adjustment	(2,186)
Balance at end of period	0
Q1 2021 Restructuring Plan [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net	5,556
Q1 2021 Restructuring Plan [Member] | Employee Severance [Member]
Restructuring Reserve [Roll Forward]
Balance at beginning of period	0
Restructuring and contract termination charges, net	5,556
Restructuring Reserve, Accrual Adjustment	0
Restructuring reserve Settled with Cash and Translation Adjustment	(917)
Balance at end of period	4,639
Q3 2020 Restructuring Plan [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net		$ 2,981
Q3 2020 Restructuring Plan [Member] | Employee Severance [Member]
Restructuring Reserve [Roll Forward]
Balance at beginning of period	1,167
Restructuring and contract termination charges, net	0
Restructuring Reserve, Accrual Adjustment	0
Restructuring reserve Settled with Cash and Translation Adjustment	(443)
Balance at end of period	724
Q1 2020 Restructuring Plan [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net			$ 4,220
Q1 2020 Restructuring Plan [Member] | Employee Severance [Member]
Restructuring Reserve [Roll Forward]
Balance at beginning of period	872
Restructuring and contract termination charges, net	0
Restructuring Reserve, Accrual Adjustment	0
Restructuring reserve Settled with Cash and Translation Adjustment	(268)
Balance at end of period	604
Q1 2020 Restructuring Plan [Member] | Facility Closing [Member]
Restructuring Reserve [Roll Forward]
Balance at beginning of period	394
Restructuring and contract termination charges, net	0
Restructuring Reserve, Accrual Adjustment	0
Restructuring reserve Settled with Cash and Translation Adjustment	(85)
Balance at end of period	309
Previous restructuring and integration plans [Member] | Employee Severance and Facility Closing [Member]
Restructuring Reserve [Roll Forward]
Balance at beginning of period	3,550
Restructuring and contract termination charges, net	0
Restructuring Reserve, Accrual Adjustment	0
Restructuring reserve Settled with Cash and Translation Adjustment	(106)
Balance at end of period	3,444
Diagnostics [Member] | Q1 2021 Restructuring Plan [Member] | Employee Severance [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net	1,615	901
Diagnostics [Member] | Q1 2021 Restructuring Plan [Member] | Facility Closing [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net	0
Diagnostics [Member] | Q3 2020 Restructuring Plan [Member] | Facility Closing [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net		0
Diagnostics [Member] | Q1 2020 Restructuring Plan [Member] | Employee Severance [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net			1,134
Diagnostics [Member] | Q1 2020 Restructuring Plan [Member] | Facility Closing [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net			682
Discovery & Analytical Solutions [Member] | Facility Relocation [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net	200		1,400
Discovery & Analytical Solutions [Member] | Q1 2021 Restructuring Plan [Member] | Employee Severance [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net	3,941
Discovery & Analytical Solutions [Member] | Q1 2021 Restructuring Plan [Member] | Facility Closing [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net	$ 0
Discovery & Analytical Solutions [Member] | Q3 2020 Restructuring Plan [Member] | Employee Severance [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net		2,080
Discovery & Analytical Solutions [Member] | Q3 2020 Restructuring Plan [Member] | Facility Closing [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net		$ 0
Discovery & Analytical Solutions [Member] | Q1 2020 Restructuring Plan [Member] | Employee Severance [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net			2,312
Discovery & Analytical Solutions [Member] | Q1 2020 Restructuring Plan [Member] | Facility Closing [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net			$ 92

Interest and Other Expense (I_3

Interest and Other Expense (Income), Net (Details) - USD ($) $ in Thousands	3 Months Ended
	Apr. 04, 2021	Apr. 05, 2020
Other Income and Expenses [Abstract]
Interest income	$ (411)	$ (265)
Interest expense	14,126	13,665
Change in fair value of financial securities	(19,298)	0
Other expense, net	(7,123)	(3,407)
Total interest and other expense, net	(12,706)	9,993
Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments	(4,700)	(9,600)
Foreign Currency Transaction Gain (Loss), before Tax	$ (1,300)	$ (7,900)

Inventories, Net (Details)

Inventories, Net (Details) - USD ($) $ in Thousands	Apr. 04, 2021	Jan. 03, 2021
Inventory Disclosure [Abstract]
Raw materials	$ 196,712	$ 205,022
Work in progress	44,676	35,160
Finished goods	288,520	274,385
Total inventories, net	$ 529,908	$ 514,567

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended
	Apr. 04, 2021	Apr. 05, 2020
Income Tax Contingency [Line Items]
Share-based Payment Arrangement, Expense	$ 5,157	$ 3,050
Provision for income taxes	101,139	974
Tax Adjustments, Settlements, and Unusual Provisions	2,000	(4,900)
Discontinued Operation, Tax Effect of Discontinued Operation	38	50
Excess Income Tax Benefit on Stock Compensation	(3,100)	(1,600)
US Federal Return To Provision Adjustments	1,800
Discrete Income Tax Expense (Benefit), Accrual For Foreign Earnings	$ 1,500
Valuation allowance adjustments [Member]
Income Tax Contingency [Line Items]
Tax Adjustments, Settlements, and Unusual Provisions		$ (3,800)

Debt (Details)

Debt (Details)	Mar. 08, 2021USD ($)	Sep. 12, 2019USD ($)	Apr. 11, 2018USD ($)	Jul. 19, 2016EUR (€)	Apr. 04, 2021USD ($)	Apr. 04, 2021EUR (€)	Jan. 03, 2021USD ($)	Jan. 03, 2021EUR (€)
2.55 Percent Senior Unsecured Notes due in 2031 [Member]
Debt Instrument, Interest Rate, Stated Percentage	2.55%
Unsecured senior notes, face value	$ 400,000,000
Gross proceeds from the issuance of debt instrument	$ 399,900,000
Senior unsecured notes issuance as percentage of principal amount	99.965%
Debt Instrument, Unamortized Discount	$ 100,000				$ 100,000
Percentage of redemption upon a change of control and a contemporaneous downgrade of the Notes	101.00%
Unamortized Debt Issuance Expense					3,800,000
2.55 Percent Senior Unsecured Notes due in 2031 [Member] | Significant Other Observable Inputs (Level 2) [Member]
Long-term Debt					$ 396,100,000
2.55 Percent Senior Unsecured Notes due in 2031 [Member] | Treasury Rate [Member]
Basis spread on variable rate					0.15%
3.625 Percent Senior Unsecured Notes due in 2051 [Member]
Debt Instrument, Interest Rate, Stated Percentage	3.625%
Unsecured senior notes, face value	$ 400,000,000
Gross proceeds from the issuance of debt instrument	$ 400,000,000
Senior unsecured notes issuance as percentage of principal amount	99.999%
Debt Instrument, Unamortized Discount	$ 4,000				$ 4,000
Percentage of redemption upon a change of control and a contemporaneous downgrade of the Notes	101.00%
Unamortized Debt Issuance Expense					4,700,000
3.625 Percent Senior Unsecured Notes due in 2051 [Member] | Significant Other Observable Inputs (Level 2) [Member]
Long-term Debt					$ 395,300,000
3.625 Percent Senior Unsecured Notes due in 2051 [Member] | Treasury Rate [Member]
Basis spread on variable rate					0.20%
Line of Credit, Maturing September 17, 2024 [Member]
Line of Credit Facility, Maximum Borrowing Capacity					$ 1,000,000,000
Aggregate borrowings under the amended facility					0		$ 158,600,000
Unamortized Debt Issuance Expense					2,400,000		2,600,000
Other Secured Bank Loan [Member]
Secured Debt | €						€ 800,000		€ 6,100,000
1.875 Percent Ten Year Senior Unsecured Notes [Member]
Debt Instrument, Interest Rate, Stated Percentage				1.875%
Unsecured senior notes, face value | €				€ 500,000,000
Gross proceeds from the issuance of debt instrument | €				€ 492,300,000
Senior unsecured notes issuance as percentage of principal amount				99.118%
Debt Instrument, Unamortized Discount				€ 4,400,000	3,000,000		3,300,000
Unamortized Debt Issuance Expense					2,700,000		2,800,000
1.875 Percent Ten Year Senior Unsecured Notes [Member] | Significant Other Observable Inputs (Level 2) [Member]
Long-term Debt					582,400,000		604,700,000
0.6 Percent Senior Unsecured Notes due in April 2021 [Member]
Debt Instrument, Interest Rate, Stated Percentage			0.60%
Unsecured senior notes, face value			$ 300,000,000
Gross proceeds from the issuance of debt instrument			$ 298,700,000
Senior unsecured notes issuance as percentage of principal amount			99.95%
Debt Instrument, Unamortized Discount			$ 200,000		656		16,200
Unamortized Debt Issuance Expense					9,631		200,000
0.6 Percent Senior Unsecured Notes due in April 2021 [Member] | Significant Other Observable Inputs (Level 2) [Member]
Long-term Debt					352,800,000		366,200,000
3.3 Percent Ten Year Senior Unsecured Notes due in Sept 2029 [Member]
Debt Instrument, Interest Rate, Stated Percentage		3.30%
Unsecured senior notes, face value		$ 850,000,000
Gross proceeds from the issuance of debt instrument		$ 847,200,000
Senior unsecured notes issuance as percentage of principal amount		99.67%
Debt Instrument, Unamortized Discount		$ 2,800,000			2,400,000		2,500,000
Unamortized Debt Issuance Expense					6,800,000		6,900,000
3.3 Percent Ten Year Senior Unsecured Notes due in Sept 2029 [Member] | Significant Other Observable Inputs (Level 2) [Member]
Long-term Debt					$ 840,800,000		$ 840,600,000
Other Debt Facilities - EUROIMMUN [Member]
Long-term Debt, Percentage Bearing Variable Interest, Amount | €						49,400
Long-term Debt, Percentage Bearing Fixed Interest, Amount | €						12,700,000
Other Debt Facilities - EUROIMMUN [Member] | Euribor Rate [Member]
Basis spread on variable rate					1.50%
United States of America, Dollars | Other Debt Facilities - EUROIMMUN [Member]
Other Long-term Debt | €						11,900,000		17,000,000
Euro Member Countries, Euro | Other Debt Facilities - EUROIMMUN [Member]
Other Long-term Debt | €						€ 10,100,000		€ 13,900,000
Minimum [Member] | Other Debt Facilities - EUROIMMUN [Member]
Debt Instrument, Interest Rate, Stated Percentage					1.10%	1.10%
Maximum [Member] | Other Secured Bank Loan [Member]
Debt Instrument, Interest Rate, Stated Percentage					8.90%	8.90%

Earnings Per Share (Schedule of

Earnings Per Share (Schedule of Reconciliation of Number of Shares Utilized in Earnings Per Share Calculations) (Details) - shares shares in Thousands	3 Months Ended
	Apr. 04, 2021	Apr. 05, 2020
Earnings Per Share [Abstract]
Number of common shares-basic	112,028	111,121
Effect of dilutive securities, Stock options	359	480
Effect of dilutive securities, Restricted stock	108	43
Number of common shares-diluted	112,495	111,644
Number of potentially dilutive securities excluded from calculation due to antidilutive impact	162	491

Industry Segment Information In

Industry Segment Information Industry Segment Information Narrative (Details)	3 Months Ended
	Apr. 04, 2021segments
Segment Reporting Information [Line Items]
Number of Operating Segment	2

Industry Segment Information (S

Industry Segment Information (Schedule of Sales and Operating Income by Operating Segment, Excluding Discontinued Operations) (Details) - USD ($) $ in Thousands	3 Months Ended
	Apr. 04, 2021	Apr. 05, 2020
Segment Reporting Information [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	$ 1,307,689	$ 652,396
Operating income (loss) from continuing operations	467,776	44,682
Interest and other (income) expense, net	(12,706)	9,993
Income from continuing operations before income taxes	480,482	34,689
Product [Member]
Segment Reporting Information [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	811,552	425,529
Service [Member]
Segment Reporting Information [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	496,137	226,867
Corporate [Member]
Segment Reporting Information [Line Items]
Operating income (loss) from continuing operations	(16,638)	(13,422)
Diagnostics [Member]
Segment Reporting Information [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	853,080	254,001
Operating income (loss) from continuing operations	441,467	29,591
Diagnostics [Member] | Product [Member]
Segment Reporting Information [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	544,297	210,173
Diagnostics [Member] | Service [Member]
Segment Reporting Information [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	308,783	43,828
Discovery & Analytical Solutions [Member]
Segment Reporting Information [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	454,609	398,395
Operating income (loss) from continuing operations	42,947	28,513
Discovery & Analytical Solutions [Member] | Product [Member]
Segment Reporting Information [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	267,255	215,356
Discovery & Analytical Solutions [Member] | Service [Member]
Segment Reporting Information [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	$ 187,354	$ 183,039

Stockholders' Equity (Narrative

Stockholders' Equity (Narrative) (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended
	Jul. 04, 2021	Apr. 04, 2021	Jan. 03, 2021	Oct. 04, 2020	Jul. 05, 2020	Apr. 05, 2020	Jul. 23, 2018
Schedule of Shareholders' Equity [Line Items]
Repurchased Common Shares For Activity Pursuant to Equity Incentive Plans		61,791
Aggregate Cost of Repurchased Common Shares for Activity Pursuant to Equity Incentive Plans		$ 9.2
Cash dividends (per share)		$ 0.07	$ 0.07	$ 0.07	$ 0.07	$ 0.07
Dividends Payable, Amount		$ 7.9
Dividends Payable, Date Declared		Jan. 28, 2021
Repurchase Program, 07/31/2020 [Member]
Schedule of Shareholders' Equity [Line Items]
Stock Repurchase Program, Authorized Amount							$ 250
Stock Repurchase Program, Remaining Authorized Repurchase Amount		$ 216.4
Number of common stock repurchased in open market		233,000
Aggregate Cost of Repurchased Common Shares Under Repurchase Program		$ 33.6
Subsequent Event [Member]
Schedule of Shareholders' Equity [Line Items]
Cash dividends (per share)	$ 0.07
Dividends Payable, Date Declared	Apr. 29, 2021

Stockholders' Equity (Component

Stockholders' Equity (Components Of Accumulated Other Comprehensive Loss) (Details) - USD ($) $ in Thousands	Apr. 04, 2021	Jan. 03, 2021
Stockholders' Equity Note [Abstract]
Foreign currency translation adjustments, net of income taxes	$ (103,242)	$ (30,937)
Unrecognized losses and prior service costs, net of income taxes	(747)	(747)
Unrealized net losses on securities, net of income taxes	(183)	(277)
Accumulated other comprehensive loss	$ (104,172)	$ (31,961)

Stock Plans (Narrative) (Detail

Stock Plans (Narrative) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Apr. 04, 2021	Apr. 05, 2020	Jan. 03, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total income tax benefit recognized for stock-based compensation	$ 4,100	$ 2,200
Stock-based compensation costs capitalized as part of inventory	500	300
Proceeds from issuance of common stock under stock plans	4,987	1,106
Share-based Payment Arrangement, Expense	$ 5,157	$ 3,050
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average grant-date fair value of options	$ 32.90	$ 18.98
Total intrinsic value of options exercised	$ 9,500	$ 900
Proceeds from issuance of common stock under stock plans	5,000	1,100
Share-based Payment Arrangement, Expense	900	1,000
Total unrecognized compensation cost, net of estimated forfeitures, related to nonvested stock, granted	$ 8,900
Weighted-average period for recognition of unrecognized compensation cost, years	2 years 3 months 18 days
Restricted Stock Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Payment Arrangement, Expense	$ 2,800	2,400
Total unrecognized compensation cost, net of estimated forfeitures, related to nonvested stock, granted	$ 23,400
Weighted-average period for recognition of unrecognized compensation cost, years	1 year 9 months 18 days
Awards/units outstanding	291,000		296,000
Number of Shares, Granted	102,000
Weighted-average grant-date fair value of stock granted (per share)	$ 129.27
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period	5,000
Fair value of restricted stock awards vested	$ 8,500	11,600
Performance Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Payment Arrangement, Expense	$ 100	$ (1,000)
Awards/units outstanding	0
Number of Shares, Granted	0
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period	0
Stock Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Granted	0
Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares authorized under plan	5,000,000
Number of Shares, Granted	58	13,612
Weighted-average grant-date fair value of stock granted (per share)	$ 136.33	$ 92.25
Shares available for grant under employee stock purchase plan	800,000
Performance Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Payment Arrangement, Expense	$ 1,400	$ 600
Awards/units outstanding	128,386
Number of Shares, Granted	77,373
Weighted-average grant-date fair value of stock granted (per share)	$ 113.44
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period	0

Stock Plans (Summary of Total C

Stock Plans (Summary of Total Compensation Recognized Related to Outstanding Stock Options) (Details) - USD ($) $ in Thousands	3 Months Ended
	Apr. 04, 2021	Apr. 05, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Payment Arrangement, Expense	$ 5,157	$ 3,050
Cost of sales [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Payment Arrangement, Expense	396	254
Research and development expenses [Member ]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Payment Arrangement, Expense	197	272
Selling, general and administrative and other expenses [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Payment Arrangement, Expense	$ 4,564	$ 2,524

Stock Plans (Weighted-Average A

Stock Plans (Weighted-Average Assumptions Used in the Black-Scholes Option Pricing Model) (Details)	3 Months Ended
	Apr. 04, 2021	Apr. 05, 2020
Share-based Payment Arrangement [Abstract]
Risk-free interest rate	0.60%	0.90%
Expected dividend yield	0.20%	0.30%
Expected lives, years	5 years	5 years
Expected stock volatility	27.30%	23.80%

Stock Plans (Summary of Stock O

Stock Plans (Summary of Stock Option Activity) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Millions	3 Months Ended
	Apr. 04, 2021	Apr. 05, 2020
Stock option activity
Number of Shares, Outstanding at beginning of period	961
Number of Shares, Granted	162
Number of Shares, Exercised	(96)
Number of Shares, Forfeited	(7)
Number of Shares, Outstanding at end of period	1,020
Number of Shares, Exercisable at end of period	640
Weighted-Average Price, Outstanding at beginning of period	$ 74.40
Weighted-Average Price, Granted	134.53
Weighted-Average Price, Exercised	53.98
Weighted-Average Price, Forfeited	88.54
Weighted-Average Price, Outstanding at end of period	85.78
Weighted-Average Price, Exercisable at end of period	$ 72.63
Weighted-Average Remaining Contractual Term in Years, Outstanding at end of period	4 years 3 months 18 days
Weighted-Average Remaining Contractual Term in Years, Exercisable at end of period	3 years 2 months 12 days
Total Intrinsic Value, Outstanding at end of period	$ 46.2
Total Intrinsic Value, Exercisable at end of period	36.7
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation costs capitalized as part of inventory	$ 0.5	$ 0.3

Stock Plans (Summary of Restric

Stock Plans (Summary of Restricted Stock Award Activity) (Details) - Restricted Stock Awards [Member] shares in Thousands	3 Months Ended
	Apr. 04, 2021$ / sharesshares
Restricted stock award activity
Number of Shares, Nonvested at beginning of period | shares	296
Number of Shares, Granted | shares	102
Number of Shares, Vested | shares	(102)
Number of Shares, Forfeited | shares	(5)
Number of Shares, Nonvested at end of period | shares	291
Weighted-Average Grant-Date Fair Value, Nonvested at beginning of period | $ / shares	$ 85.67
Weighted-Average Grant-Date Fair Value, Granted | $ / shares	129.27
Weighted-Average Grant-Date Fair Value, Vested | $ / shares	83.16
Weighted-Average Grant-Date Fair Value, Forfeited | $ / shares	86.90
Weighted-Average Grant-Date Fair Value, Nonvested at end of period | $ / shares	$ 101.83

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets, Net (Narrative) (Details) - USD ($) $ in Thousands	Jan. 04, 2021	Apr. 04, 2021	Apr. 05, 2020	Jan. 03, 2021
Goodwill and Intangible Assets Net [Line Items]
Change in any one of the input assumptions for the various reporting units	10.00%
Goodwill		$ 3,683,790		$ 3,447,114
Total amortization expense related to finite-lived intangible assets		54,200	$ 47,300
Future Amortization Expense, Remainder of Fiscal Year		167,100
Future Amortization Expense, Year One		205,400
Future Amortization Expense, Year Two		182,000
Future Amortization Expense, Year Three		161,500
Future Amortization Expense, Year Four		133,700
Finite-Lived Intangible Assets, Net		1,402,672		1,295,109
Intangible assets, net		1,473,256		1,365,693
Minimum [Member]
Goodwill and Intangible Assets Net [Line Items]
Long-term terminal growth rates for reporting units	3.00%
Discount rates for reporting units	8.00%
Maximum [Member]
Goodwill and Intangible Assets Net [Line Items]
Long-term terminal growth rates for reporting units	5.00%
Discount rates for reporting units	12.50%
Patents [Member]
Goodwill and Intangible Assets Net [Line Items]
Gross amortizable intangible assets		30,843		30,855
Less: Accumulated amortization		28,484		28,440
Finite-Lived Intangible Assets, Net		2,359		2,415
Trade Names And Trademarks [Member]
Goodwill and Intangible Assets Net [Line Items]
Gross amortizable intangible assets		120,444		98,661
Less: Accumulated amortization		49,853		48,806
Finite-Lived Intangible Assets, Net		70,591		49,855
Licensing Agreements [Member]
Goodwill and Intangible Assets Net [Line Items]
Gross amortizable intangible assets		58,705		58,700
Less: Accumulated amortization		53,005		52,452
Finite-Lived Intangible Assets, Net		5,700		6,248
Core Technology [Member]
Goodwill and Intangible Assets Net [Line Items]
Gross amortizable intangible assets		936,682		789,799
Less: Accumulated amortization		411,558		398,992
Finite-Lived Intangible Assets, Net		525,124		390,807
Customer Relationships [Member]
Goodwill and Intangible Assets Net [Line Items]
Gross amortizable intangible assets		1,334,715		1,357,660
Less: Accumulated amortization		546,783		522,820
Finite-Lived Intangible Assets, Net		787,932		834,840
In-process Research and Development [Member]
Goodwill and Intangible Assets Net [Line Items]
Gross amortizable intangible assets		$ 10,966		$ 10,944
Tulip Diagnostics Private Limited [Member]
Goodwill and Intangible Assets Net [Line Items]
Goodwill	$ 77,800

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets, Net (Changes in the Carrying Amount of Goodwill) (Details) $ in Thousands	3 Months Ended
	Apr. 04, 2021USD ($)
Changes in the carrying amount of goodwill
Balance at beginning of period	$ 3,447,114
Foreign currency translation	(45,387)
Goodwill, Acquisition, Earn Outs and Other Adjustments	282,063
Balance at end of period	3,683,790
Diagnostics [Member]
Changes in the carrying amount of goodwill
Balance at beginning of period	1,691,227
Foreign currency translation	(22,268)
Goodwill, Acquisition, Earn Outs and Other Adjustments	280,737
Balance at end of period	1,949,696
Discovery & Analytical Solutions [Member]
Changes in the carrying amount of goodwill
Balance at beginning of period	1,755,887
Foreign currency translation	(23,119)
Goodwill, Acquisition, Earn Outs and Other Adjustments	1,326
Balance at end of period	$ 1,734,094

Goodwill and Intangible Asset_5

Goodwill and Intangible Assets, Net (Identifiable Intangible Asset Balances) (Details) - USD ($) $ in Thousands	Apr. 04, 2021	Jan. 03, 2021
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Net amortizable intangible assets	$ 1,402,672	$ 1,295,109
Intangible assets, net	1,473,256	1,365,693
Patents [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Gross amortizable intangible assets	30,843	30,855
Less: Accumulated amortization	(28,484)	(28,440)
Net amortizable intangible assets	2,359	2,415
Trade Names And Trademarks [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Gross amortizable intangible assets	120,444	98,661
Less: Accumulated amortization	(49,853)	(48,806)
Net amortizable intangible assets	70,591	49,855
Trade names and trademarks	70,584	70,584
Licensing Agreements [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Gross amortizable intangible assets	58,705	58,700
Less: Accumulated amortization	(53,005)	(52,452)
Net amortizable intangible assets	5,700	6,248
Core Technology [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Gross amortizable intangible assets	936,682	789,799
Less: Accumulated amortization	(411,558)	(398,992)
Net amortizable intangible assets	525,124	390,807
Customer Relationships [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Gross amortizable intangible assets	1,334,715	1,357,660
Less: Accumulated amortization	(546,783)	(522,820)
Net amortizable intangible assets	787,932	834,840
In-process Research and Development [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Gross amortizable intangible assets	$ 10,966	$ 10,944

Warranty Reserves (Details)

Warranty Reserves (Details) - USD ($) $ in Thousands	3 Months Ended
	Apr. 04, 2021	Apr. 05, 2020
Warranty reserve activity
Balance beginning of period	$ 12,073	$ 8,812
Provision charged to income	3,691	2,712
Payments	(6,182)	(3,266)
Adjustments to previously provided warranties, net	2,455	1,052
Foreign currency translation and acquisitions	(190)	(269)
Balance end of period	$ 11,847	$ 9,041

Employee Benefit Plans (Compone

Employee Benefit Plans (Components of Net Periodic Benefit Cost (Credit)) (Details) - USD ($) $ in Thousands	3 Months Ended
	Apr. 04, 2021	Apr. 05, 2020
Defined Benefit Pension Benefits [Member]
Components of net periodic benefit cost (credit)
Service cost	$ 1,334	$ 1,907
Interest cost	2,377	3,144
Expected return on plan assets	(6,127)	(5,384)
Net periodic benefit cost (credit)	(2,416)	(333)
Postretirement Medical Benefits [Member]
Components of net periodic benefit cost (credit)
Service cost	14	18
Interest cost	17	24
Expected return on plan assets	(397)	(347)
Net periodic benefit cost (credit)	(366)	(305)
UNITED STATES
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Plan Assets, Contributions by Employer	20,000
Foreign Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Plan Assets, Contributions by Employer	$ 1,800	$ 2,100

Derivatives And Hedging Activ_2

Derivatives And Hedging Activities (Details) $ in Thousands, € in Millions	3 Months Ended
	Apr. 04, 2021USD ($)	Apr. 04, 2021EUR (€)	Apr. 05, 2020USD ($)	Jan. 03, 2021USD ($)	Jan. 03, 2021EUR (€)	Apr. 05, 2020EUR (€)
Derivative [Line Items]
Company's business conducted outside United States	70.00%	70.00%
Payments for (Proceeds from) Hedge, Financing Activities	$ (6,005)		$ (8,708)
Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net	0
Foreign Currency Transaction Gain (Loss), before Tax	$ (1,300)		(7,900)
European And Asian Currencies [Member]
Derivative [Line Items]
Maximum maturity period for foreign exchange contracts, in months	12 months	12 months
Duration Of Foreign Currency Derivatives	30 days	30 days
Cash Flow Hedging [Member] | 1.875 Percent Ten Year Senior Unsecured Notes [Member]
Derivative [Line Items]
Unrealized Gain (Loss) on Derivatives	$ 900
Derivative, Notional Amount	197,400
Cash Flow Hedging [Member] | 0.6 Percent Senior Unsecured Notes due in April 2021 [Member]
Derivative [Line Items]
Unrealized Gain (Loss) on Derivatives	(13,600)
Derivative, Notional Amount	300,000
Fair Value Hedging [Member]
Derivative [Line Items]
Derivative, Notional Amount	969,500		272,400	$ 808,000
Notional Amount of Euro Derivatives [Member]
Derivative [Line Items]
Derivative, Notional Amount | €					€ 33.4	€ 108
Notional Amount of US Dollar Derivatives [Member] | Cash Flow Hedging [Member]
Derivative [Line Items]
Derivative, Notional Amount	1,309,000		138,900	$ 499,000
Net Investment Hedging [Member] | 1.875 Percent Ten Year Senior Unsecured Notes [Member]
Derivative [Line Items]
Notional Amount of Nonderivative Instruments | €		€ 299.7
Unrealized Gain (Loss) on Net Investment Hedge in AOCI	$ 21,600		21,000
United States of America, Dollars | Cross-currency Swap [Member]
Derivative [Line Items]
Derivative, Fixed Interest Rate	5.00%
United States of America, Dollars | Net Investment Hedging [Member] | Cross-currency Swap [Member]
Derivative [Line Items]
Notional Amount of Nonderivative Instruments	$ 220,000
Unrealized Gain (Loss) on Net Investment Hedge in AOCI	(10,100)		$ 8,900
Fair Value of Cross-currency Swap	$ (10,100)
Euro Member Countries, Euro | Cross-currency Swap [Member]
Derivative [Line Items]
Derivative, Fixed Interest Rate	2.47%
Euro Member Countries, Euro | Net Investment Hedging [Member] | Cross-currency Swap [Member]
Derivative [Line Items]
Notional Amount of Nonderivative Instruments	$ 197,400

Fair Value Measurements (Narrat

Fair Value Measurements (Narrative) (Details) € in Millions	3 Months Ended
	Apr. 04, 2021USD ($)	Apr. 04, 2021EUR (€)	Mar. 08, 2021USD ($)	Jan. 03, 2021USD ($)	Jan. 03, 2021EUR (€)	Apr. 05, 2020USD ($)	Dec. 29, 2019USD ($)	Sep. 12, 2019USD ($)	Apr. 11, 2018USD ($)	Jul. 19, 2016EUR (€)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	$ 7,300,000
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value	$ 3,124,000			$ 2,953,000		$ 22,777,000	$ 35,481,000
Business Combination, Contingent Consideration Arrangements, Description	Contingent consideration is measured at fair value at the acquisition date, based on the probability that revenue thresholds or product development milestones will be achieved during the earnout period, with changes in the fair value after the acquisition date affecting earnings to the extent it is to be settled in cash.
Business Combination, Contingent Consideration Arrangements, Maximum Period	1 year 9 months 18 days
Business Combination, Contingent Consideration Arrangements, Weighted Average Period	1 year 1 month 6 days
2.55 Percent Senior Unsecured Notes due in 2031 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Unamortized Debt Issuance Expense	$ 3,800,000
Unsecured senior notes, face value			$ 400,000,000
Debt Instrument, Unamortized Discount	(100,000)		(100,000)
3.625 Percent Senior Unsecured Notes due in 2051 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Unamortized Debt Issuance Expense	4,700,000
Unsecured senior notes, face value			400,000,000
Debt Instrument, Unamortized Discount	(4,000)		$ (4,000)
Line of Credit, Maturing September 17, 2024 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity	1,000,000,000
Revolving credit facility outstanding balance	0			158,600,000
Unamortized Debt Issuance Expense	2,400,000			2,600,000
1.875 Percent Ten Year Senior Unsecured Notes [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Unamortized Debt Issuance Expense	2,700,000			2,800,000
Unsecured senior notes, face value | €										€ 500
Debt Instrument, Unamortized Discount	(3,000,000)			(3,300,000)						€ (4.4)
0.6 Percent Senior Unsecured Notes due in April 2021 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Unamortized Debt Issuance Expense	9,631			200,000
Unsecured senior notes, face value									$ 300,000,000
Debt Instrument, Unamortized Discount	(656)			(16,200)					$ (200,000)
3.3 Percent Ten Year Senior Unsecured Notes due in Sept 2029 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Unamortized Debt Issuance Expense	6,800,000			6,900,000
Unsecured senior notes, face value								$ 850,000,000
Debt Instrument, Unamortized Discount	(2,400,000)			(2,500,000)				$ (2,800,000)
Other Debt Facilities - EUROIMMUN [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term Debt, Percentage Bearing Fixed Interest, Amount | €		€ 12.7
Other Debt Facilities - EUROIMMUN [Member] | Euro Member Countries, Euro
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Other Long-term Debt | €		10.1			€ 13.9
Other Debt Facilities - EUROIMMUN [Member] | United States of America, Dollars
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Other Long-term Debt | €		11.9			17
Senior Unsecured Notes [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Unsecured senior notes, fair value	2,710,000,000			1,984,300,000
Significant Other Observable Inputs (Level 2) [Member] | 2.55 Percent Senior Unsecured Notes due in 2031 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term Debt	396,100,000
Significant Other Observable Inputs (Level 2) [Member] | 3.625 Percent Senior Unsecured Notes due in 2051 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term Debt	395,300,000
Significant Other Observable Inputs (Level 2) [Member] | 1.875 Percent Ten Year Senior Unsecured Notes [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term Debt	582,400,000			604,700,000
Significant Other Observable Inputs (Level 2) [Member] | 0.6 Percent Senior Unsecured Notes due in April 2021 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term Debt	352,800,000			366,200,000
Significant Other Observable Inputs (Level 2) [Member] | 3.3 Percent Ten Year Senior Unsecured Notes due in Sept 2029 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term Debt	840,800,000			840,600,000
Significant Other Observable Inputs (Level 2) [Member] | Senior Unsecured Notes [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term Debt	$ 2,567,500,000			$ 1,811,500,000
Significant Other Observable Inputs (Level 2) [Member] | Other Debt Facilities, including the senior revolving credit facility [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Other Long-term Debt | €		€ 12.7			€ 179.1

Fair Value Measurements (Assets

Fair Value Measurements (Assets and Liabilities Carried at Fair Value Measured on a Recurring Basis) (Details) - USD ($) $ in Thousands	Apr. 04, 2021	Jan. 03, 2021	Apr. 05, 2020	Dec. 29, 2019
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value	$ 3,124	$ 2,953	$ 22,777	$ 35,481
Fair Value, Recurring [Member] | Carrying (Reported) Amount, Fair Value Disclosure [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	41,531	2,154
Foreign exchange derivative assets, net	(17,840)	(31,248)
Foreign exchange derivative liabilities, net	(18,561)	(21,413)
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value	3,124	2,953
Fair Value, Recurring [Member] | Quoted Prices In Active Markets (Level 1) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	41,531	2,154
Foreign exchange derivative assets, net	0	0
Foreign exchange derivative liabilities, net	0	0
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value	0	0
Fair Value, Recurring [Member] | Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	0	0
Foreign exchange derivative assets, net	(17,840)	(31,248)
Foreign exchange derivative liabilities, net	(18,561)	(21,413)
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value	0	0
Fair Value, Recurring [Member] | Significant Unobservable Inputs (Level 3) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	0	0
Foreign exchange derivative assets, net	0	0
Foreign exchange derivative liabilities, net	0	0
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value	$ 3,124	$ 2,953

Fair Value Measurements (Reconc

Fair Value Measurements (Reconciliation of Beginning and Ending Level 3 Net Liabilities) (Details) - USD ($) $ in Thousands	3 Months Ended
	Apr. 04, 2021	Apr. 05, 2020	Jan. 03, 2021
Fair Value Disclosures [Abstract]
Balance beginning of period	$ (2,953)	$ (35,481)
Payments	69	379
Change in fair value (included within selling, general and administrative expenses)	(240)	12,325
Balance end of period	(3,124)	$ (22,777)
Business Combination, Contingent Consideration, Liability	$ (3,100)		$ (3,000)

Contingencies (Details)

Contingencies (Details) $ in Millions	3 Months Ended
	Apr. 04, 2021USD ($)years	Jan. 03, 2021USD ($)
Commitments and Contingencies Disclosure [Abstract]
Management's estimate of total cost of ultimate disposition | $	$ 12.1	$ 12.9
Number of years over which estimated environmental cost will be paid | years	10

Uncategorized Items - pki-20210

Label	Element	Value
Restricted Cash	us-gaap_RestrictedCash	$ 23,000
Restricted Cash	us-gaap_RestrictedCash	$ 2,167,000